S-nitrosation of mitochondrial Connexin 43 regulates mitochondrial function: implication for cardioprotection by Soetkamp, Daniel
  
  
 
S-nitrosation of mitochondrial  
Connexin 43 regulates mitochondrial function: 
implication for cardioprotection 
 
 
 
Inauguraldissertation 
zur Erlangung des Grades eines Doktors der Naturwissenschaften  
     (Dr. rer.nat.) 
des Fachbereichs Biologie und Chemie 
der Justus-Liebig-Universität Gießen 
  
 
 
vorgelegt von 
Soetkamp, Daniel 
aus Münster 
  
  
  
 
Gießen, September 2014 
Die der vorliegenden Arbeit zugrunde liegenden Experimente wurden am Institut für 
Physiologie der Justus-Liebig Universität oder an anderen gleichwertigen Einrichtung 
unter der Leitung von Herrn Prof. Dr. Schulz durchgeführt.  
  
1. Gutachter: Herr Prof. Dr. Michael Martin  
2. Gutachter: Herr Prof. Dr. Rainer Schulz  
  
Vorsitzender des Prüfungsausschusses: Herr Prof. Dr. Herbert Over  
 
 
Tag der Disputation:  05.09.2014 
 
  
 
If you want to make an apple pie from scratch, you must first create the 
universe. 
Dr. Carl Sagan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents   I 
 
Table of Contents 
1. Introduction ........................................................................................................... 1 
1.1 Connexins....................................................................................................... 1 
1.2 Gap junctions and hemichannels .................................................................... 2 
1.3 Regulation of connexin ................................................................................... 4 
1.4 Myocardial ischemia/reperfusion injury and its reduction by preconditioning . 7 
1.5 Role of Cx43 in cardioprotection by preconditioning (PC) .............................. 9 
1.6 NO in cardioprotection .................................................................................. 10 
1.7 Aim of study .................................................................................................. 13 
2. Materials and Methods ....................................................................................... 14 
2.1 Materials ....................................................................................................... 14 
2.1.1 Chemicals .............................................................................................. 14 
2.1.2 Antibodies and enzymes ........................................................................ 17 
2.1.3 Kits ......................................................................................................... 18 
2.1.4 Buffer and solutions ............................................................................... 18 
2.1.5 Consumables ......................................................................................... 20 
2.1.6 Equipment .............................................................................................. 20 
2.2 Methods ........................................................................................................ 21 
2.2.1 Animals .................................................................................................. 21 
2.2.2 Isolation of mitochondria ........................................................................ 22 
2.2.3 Analyses of mitochondrial membrane potential ...................................... 23 
2.2.4 Measurements of mitochondrial autofluorescence ................................. 23 
2.2.5 Dye permeation experiments ................................................................. 24 
2.2.6 Mitochondrial potassium uptake ............................................................. 24 
2.2.7 Mitochondrial sodium uptake ................................................................. 25 
2.2.8 ROS production ..................................................................................... 26 
2.2.9 Rat heart perfusion protocols ................................................................. 26 
2.2.10 In vivo remote ischemic preconditioning ............................................. 27 
2.2.11 Labeling and precipitation of SNO modified proteins .......................... 27 
2.2.12 Analysis of NO donor impact on mtCx43 phosphorylation .................. 28 
2.2.13 Western blot analysis .......................................................................... 28 
2.2.14 Precipitation of mtCx43 and SNO labeling for proteomic analysis ...... 29 
2.2.15 Identification of SNO cysteine residues by LC-MS/MS analysis ......... 30 
II   Table of Contents 
2.2.16 MASCOT database analysis ............................................................... 31 
2.2.17 Statistics ............................................................................................. 31 
3. Results ............................................................................................................... 32 
3.1 SNO of mtCx43 influences mitochondrial function ........................................ 32 
3.1.1 Estimation of carbenoxolone toxicity ...................................................... 32 
3.1.2 Analysis of NO’s impact on mitochondrial permeability .......................... 34 
3.1.3 Mitochondrial potassium uptake ............................................................. 38 
3.1.4 Mitochondrial sodium uptake ................................................................. 43 
3.1.5 ROS production ..................................................................................... 47 
3.1.6 Quantification of SNO modified mtCx43 after NO donor application ...... 52 
3.1.7 Identification of mtCx43 phosphorylation induced by NO ....................... 54 
3.2 The link between SNO of mtCx43 and the signal transduction cascade of 
preconditioning ....................................................................................................... 56 
3.2.1 Analysis of mitochondrial dye permeability after IPC ............................. 56 
3.2.2 Quantification of SNO modified mtCx43 after IPC ................................. 57 
3.2.3 Quantification of SNO modified mtCx43 after rIPC ................................ 60 
3.2.4 Identification of SNO modified cysteine residues of mtCx43 .................. 61 
4. Discussion .......................................................................................................... 64 
4.1 S-nitrosation of mtCx43 influences mitochondrial function ........................... 64 
4.1.1 Reduction of mitochondrial permeability by carbenoxolone confirms the 
existence of mtCx43 hemichannels .................................................................... 64 
4.1.2 NO increases mitochondrial permeability ............................................... 65 
4.1.3 Ion specificity of NO mediated increased mitochondrial permeability .... 67 
4.1.4 NO mediated increase in ROS formation in SSM via Cx43 .................... 69 
4.1.5 Potential side effects of applied NO donors ........................................... 70 
4.1.6 Increase in SNO of mtCx43 by application of NO donors ...................... 71 
4.2 IPC induction of SNO of mtCx43 may mediate cardioprotection .................. 71 
4.3 Study limitations ........................................................................................... 73 
5. Summary ............................................................................................................ 75 
6. Zusammenfassung ............................................................................................. 77 
List of Abbreviations .................................................................................................. 79 
List of Figures ............................................................................................................ 83 
List of Tables ............................................................................................................. 85 
Reference List ........................................................................................................... 86 
Table of Contents   III 
 
Publications ............................................................................................................. 106 
Presentations (Poster) ............................................................................................. 106 
Selbstständigkeitserklärung ..................................................................................... 107 
Acknowledgements .................................................................................................. 108 
Curriculum Vitae ...................................................................................................... 110 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
Dedicated to 
Nesrin, Gabriel, Theo, and Lisa 
 
 
 
 
 
 
 
 
 

Introduction   1 
 
 
1. Introduction 
Connexins (Cxs) are a family of integral membrane proteins. They are the basis of 
channels within membranes allowing the passage of ions and small molecules. 
These channels are essential in various aspects of vertebrate physiology including 
the coordination of cellular signaling.  
 
1.1 Connexins  
Humans express 21 different connexin (Cx) isoforms, whereas mouse and rat 
express only 20. Cxs are named according to their molecular weight, which ranges 
from 23 to 62 kDa. Channels formed by different Cxs vary in solute permeability and 
their regulation and interaction with other proteins [1, 126, 182, 198]. Cxs are 
transmembrane (TM) proteins spanning the plasma membrane four times. The TM 
domain consists of α-helices (TM1-TM4) extending outside the plasma membrane for 
a significant distance. TM1 and TM2 domains are the pore forming helices with their 
narrowest region near to the extracellular site of the plasma membrane [174, 198]. 
The short N-terminal and the longer C-terminal ends face the cytosol. The C-terminal 
domain displays large variations among connexin isoforms. Two extracellular loops 
(E1 and E2 between TM1-TM2 and TM3-TM4) and one cytoplasmic loop (CL 
between TM2-TM3), with a not well conserved sequence, connect the TM domains 
[1, 126, 198].  
In the heart, a variety of Cx isoforms are present. Cx31.9 is located at the 
atrioventricular nodal region [40]. Cx40 is present in the atrium and Cx45 at the 
border between myocytes and fibroblasts. Both Cx40 and Cx45 are also found in the 
conduction system [44]. In endothelial cells Cx43, Cx40, and Cx37 are detectable 
[34]. However, the predominant isoform in cardiomyocytes is Cx43. The majority of 
cellular Cx43 forms gap junctions (GJs) at the terminal intercalated disks of 
cardiomyocytes. However, in low density Cx43 is also located at the lateral sides of 
the cardiomyocyte sarcolemma where it forms hemichannels (HCs) [78, 185, 223].  
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The C-terminal tail of Cx43 contains a variety of domains interacting with other 
proteins such as tubulins, tyrosine kinases, ubiquitin ligases, zonula occludens 1, and 
sodium (Na+) channels [3, 4, 117, 256, 291]. Furthermore, phosphorylation mainly 
takes place at the C-terminal domain. Thus far, three distinct forms of Cx43 (P0, P1, 
P2) with different molecular weights have been detected in the heart by Western blot 
analysis. P0 has been viewed as dephosphorylated Cx43 while P2 is believed to 
represent the fully phosphorylated form of Cx43 [278]. Cx43-phosphorylation sites 
are species-dependent: in mice there are 24 identified sites, in rats 21, and in 
humans 19 sites [127, 278]. These sites are the target of several kinases, such as 
protein kinase A (PKA), protein kinase C (PKC), protein kinase G (PKG), protein 
tyrosine kinases, mitogen-activated protein kinases (MAPK), casein kinases and 
protein phosphatases [158, 242]. 
 
1.2 Gap junctions and hemichannels 
Six Cx43 assemble to form HCs, which contribute to cellular volume regulation [218], 
the release of ATP and NAD+ from the cytosol [71], and the release of signaling 
molecules into the extracellular fluid activating survival pathways [55]. The two 
extracellular loops of Cx43 contain six conserved cysteines that can form 
Figure 1.1: Schematic display of rat Cx43. Schematic representation of the 
primary structure of Cx43 and its orientation in the outer membrane.  Cysteine 
residues of the amino acid sequence are labeled in red [modified from Lampe and 
Lau, 2000].   
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intramolecular disulfide bonds. These disulfide bonds are essential for connecting two 
opposing HCs of neighboring cells thereby forming a pore. Accumulation of pores 
form GJs [9, 90, 233], which connect the cytosol of neighboring cells allowing the 
passage of molecules with a size up to 1 kDa [89, 130]. GJs have been characterized 
as unspecific aqueous pores with a diameter of 0.8–1.4 nm, which is the only 
selective parameter [175]. There is certain evidence that casts doubt on the 
unselectively of Cx-formed channels. First, the permeability to fluorescence dyes 
decreases with increasing negative charge of the dye molecule, which suggests that 
the Cx-formed channel pore has a slight, fixed negative charge [32, 89]. Supporting  
this observation is the relatively low chloride (Cl-)/ potassium (K+) permeability 
compared to Na+/K+ for GJs determined by yj ratios or bi-ionic potentials [33, 196, 
281]. Secondly, according to several studies, Cx-formed channels are highly selective 
for monovalent cations with a higher permeability for K+ than Na+ (suggested ranking: 
K>Na>Lithium (Li)>Trimethylaluminium (TMA)> Triethanolamine (TEA)) [17, 33, 142, 
262, 279, 280, 287]. However, the main forces determining fluxes via membranes are 
chemical and electrical gradients between membranes. Fluxes of molecules through 
GJs and HCs are regulated by channel assembly and degradation [233], as well as 
by channel open probability [259]. Cx43 GJs are highly dynamic structures with a 
high turnover rate of a few hours (half-life of Cx43 ranges from 1–3 hours) and a 
rapid redistribution [15, 157, 255].   
 
 
 
Figure 1.2: Schematic illustration of GJ assembly.  
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1.3 Regulation of connexin 
The regulation of pore diameter and open probability of Cx-formed GJs and HCs is a 
complex mechanism and is so far not fully understood. Several Cx domains are 
involved in Cx43-formed channel opening. The N-terminal domain is involved in 
voltage-dependent gating [11, 98, 154, 215], while the C-terminal domain is involved 
in regulation of open probability and protein-protein interactions [1, 3, 91, 117, 126]. 
The CL region interacts with the C-terminal domain regulating channel opening 
during cellular acidification [73, 121].   
GJs are mostly open for mediating continuous electric and chemical signals between 
cells, whereas HCs at the sarcolemma have a low open probability. Nevertheless the 
low open probability of HCs is enough to release signaling molecules of a 
physiological relevant amount into the extracellular space. Thus, HCs are involved in 
autocrine and paracrine signaling under physiological conditions [39, 52, 260, 298]. 
The p38 mitogen-activated protein kinase dependent pathway on the one hand 
reduces communication via GJs while on the other hand increases HCs permeability. 
The cytokine mediated increase in HCs permeability is blocked by application of a 
sulfhydryl reducing agent, which, however, does not affect GJs permeability. This 
finding suggests, that both types of Cx-formed channels are targeted by PKs, but 
their functional response is different [225].   
Ions which can pass through Cx43-formed channels are able to regulate its 
conductance. Calcium (Ca2+) induced reduction of GJ open probability has been 
reported for cardiomyocytes [72, 199]. Large changes in Ca2+ concentrations reduce 
gap junction conduction, whereas a low concentration does not affect GJ permeability 
[180, 232]. The suggested binding site of the positively charged Ca2+ and proton (H+) 
ions is located at the CL [259].    
In addition, Cx-formed HC open probability is regulated by Ca2+. HC open probability 
is enhanced by a positive membrane potential and low extracellular Ca2+ levels [59, 
86, 98, 163]. Under pathological conditions, sustained HC opening leads to 
metabolite loss, Ca2+ influx, equilibration of ionic gradients, and cellular damage. 
Blockade of HC opening reduces cardiomyocyte volume overload and irreversible 
injury following ischemia/reperfusion [289]. Under physiological conditions, the 
negative voltage of the membrane on the cellular side and millimolar concentrations 
of extracellular Ca2+ keep the HC open probability low [41, 48, 59, 86, 98, 163, 238]. 
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However, HC opening can still be induced at high extracellular Ca2+ by several 
factors, including ischemia, inflammation, extracellular alkalinization, and Cx 
dephosphorylation [8, 60, 83, 113, 136, 166, 202, 227, 239, 251].  
The phosphorylation of Cx43 at serine, threonine, and tyrosine residues mediates GJ 
remodeling and HC opening at the plasma membrane during ischemic events in the 
brain, kidney, and heart [59, 78, 113, 165]. Phosphorylation of Cx43 affects GJ 
communication in a positive and negative manner [21, 35, 64, 139, 157, 193]. The 
site specific phosphorylation sites of Cx43 targeted by PKC, MAPK, and protein-
tyrosine kinase pp60src, have been identified (Figure 1.3) [159, 172, 234, 290].  
Phosphorylation of Ser368 by PKC decreases the selectivity for large hydrophilic 
compounds and negatively charged solutes, while increasing the selectivity for 
positively charged ions, which maintains electrical cell-cell coupling [10, 81, 155, 
159]. During ischemia this mechanism minimizes the spread of damage inducing 
compounds to healthy neighboring cells. Furthermore, Cx43 phosphorylation is 
involved in its intracellular transportation as well as the assembly of GJs which 
influence intercellular communication [284].   
On the other hand, dephosphorylation of Ser368 increases HC-permeability and 
thereby increasing the fluxes of metabolites and second messengers, Ca2+ induced 
cellular damage, and subsequently induces apoptosis [60, 113, 136, 161, 165, 283]. 
Studies using liposomes with nonphosphorylated Cx43-formed HCs have shown low 
permeability, whereas liposomes with induced HC phosphorylation showed greater 
permeability, indicating that dephosphorylation can be sufficient for HC opening. 
Supporting this notion, channels formed by mutated Cx43 - without the Ser368 
phosphorylation site - stay preferentially open [10]. However, this effect was 
exclusively found for Cx43 at the intercalated disks and Ser368 phosphorylation was 
not found elsewhere [81, 176, 256, 258].  
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Therefore, there are specific ways of increasing HC permeability: dephosphorylation 
by ATP depletion, activation of Ca2+ dependent phosphatases, oxidation by reactive 
oxygen species (ROS) [61], and a rapid turnover rate of Cx43 by additional insertion 
of HCs into the membrane [224]. Indeed, HC opening in astrocytes is blocked during 
metabolic inhibition by scavenging ROS with Trolox. Interestingly, in the metabolically 
inhibited astrocytes treated with cyclosporine A (CsA), an increase in HC permeability 
was still possible even though dephosphorylation was inhibited. In fact, this suggests 
that the redox potential plays a role in HC opening [60, 61, 224]. Supporting this 
notion, Tumor necrosis factor (TNF-α) and interleukin-1β induced p38 MAPK 
activation leads to an increase in nitric oxide (NO) synthase (NOS) activity, which 
induces Cx43 HC opening in astrocytes [51, 216, 224, 226, 294]. Accordingly, 
application of low concentrations of NO induces increased Cx43 HC permeability. 
The free radical NO can attach covalently to free thiol groups of cysteine residues, 
which is a reversible redox-dependent post-translational protein modification called S-
nitrosation (SNO) [82]. Studies have shown that NO and metabolic inhibition 
increases the permeability of Cx-formed channels to hydrophilic fluorescent 
molecules in astrocytes. Agents like Trolox and melatonin, which scavenge free 
Figure 1.3: Schematic representation of the primary structure of 
rat Cx43 and its phosphorylation sites targeted by v-Src, MAPK, 
and PKC [modified from Lampe and Lau, 2000].  
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radicals like NO, lower dye uptake by reducing SNO without affecting Cx43 
phosphorylation, whereas application of NO donors increase dye uptake. This 
suggests that SNO and not Cx43 dephosphorylation is the critical factor for increased 
Cx43-formed channel open probability [224]. Furthermore, SNO of the cysteine 
residue 271 increases and denitrosation decreases permeability of Cx43 
myoendothelial GJs in the vessel wall [261]. Apart from its pore-forming capabilities, 
Cx43 interacts with a great variety of intracellular proteins involved in intracellular 
signaling and breakdown products of Cx43 (such as its C-terminus) might act as 
transcription factor [27]. The C-terminal domain of rat Cx43 was detected in the 
nucleus of cardiomyocytes and HeLa cells, where it inhibits cell proliferation [65].      
  
1.4 Myocardial ischemia/reperfusion injury and its 
reduction by preconditioning  
Myocardial infarction occurs species-dependently during occlusion of a major 
coronary artery for more than 20 minutes. While reperfusion is mandatory to 
ultimately reduce infarct size, reperfusion itself might contribute to the development of 
irreversible myocardial injury (the so called reperfusion injury). Since the extent of 
myocardial infarction predicts patient’s prognosis, the search for strategies to reduce 
irreversible myocardial injury is still ongoing [109].  
  
 
Figure 1.4: Time course of myocardial infarct development following complete coronary occlusion 
in different species [modified from Schaper et al., 1988].   
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Interestingly, brief episodes of ischemia and reperfusion protect the heart and delay 
the irreversible tissue damage caused by a subsequent more prolonged ischemia 
and reperfusion. This phenomenon has been termed ischemic preconditioning (IPC) 
and was first described by Murry et al. [56, 192]. IPC reduces the extent of apoptosis 
[179, 192, 195, 209], reduces the infarct size [299], and protects against arrhythmia in 
mice [236], rats [104, 249, 285], rabbit [57], and dog [143], but not in pig [102, 203, 
228, 248]. The trigger phase of IPC is characterized by release of adenosine, 
bradykinin, opioids, and other G-protein coupled membrane receptor activating 
pathways [18, 19, 93, 100, 153, 171, 194, 201, 272] such as reperfusion injury 
salvage kinases (RISK) and survivor activating factor enhancement (SAFE) 
pathways. While the kinases of RISK (Akt/ERK1/2/GSK-3β), kinases of SAFE (TNF-
α/JAK/STAT-3) [25, 85, 112, 119, 187, 189], and the protein kinase G/PKC pathway 
[63], contribute to cell survival, the modulation of AMP-activated protein kinase, Pim-
1, and proteins of the Bcl-2 family may also play a role [16, 46, 49, 50, 129, 188]. 
Preconditioning can also be induced by pharmacological agents, for example by 
potassium channel openers like diazoxide, pinacidil, and nicorandil [115, 204, 237]. 
Diazoxide is supposed to be a selective mitochondrial ATP-dependent potassium 
(mitoKATP) channel opener inducing a low conduction state of the mitochondrial 
permeability transition pore (MPTP) located in the inner mitochondrial membrane. 
Prolonged opening of the MPTP destroys the proton gradient and thus the 
mitochondrial membrane potential, leads to mitochondrial swelling, rupture of the 
outer and inner mitochondrial membrane and finally loss of cardiomyocyte viability 
[144].  
Short episodes of ischemia and reperfusion applied at a distant tissue or organ, such 
as extremities, also render the heart resistant to a prolonged period of ischemia, 
thereby inducing a phenomenon called remote ischemic preconditioning (rIPC) [31, 
111, 213, 214, 271]. Recent studies showed that rIPC limited the injury in patients 
with acute myocardial infarction [69]. The protective signal is supposed to be directed 
to the heart by the interaction of humoral factors and neuronal transmission [2, 74, 
75, 95, 135, 169, 250]. An increasing amount of data suggests that rIPC has 
protective mechanisms/signaling cascades in common with IPC. Signaling molecules 
such as adenosine, bradykinin, and opioids also trigger cardioprotection by rIPC. 
Furthermore, activity of common cardiac prosurvival kinases are also upregulated 
and increased phosphorylation was detected for ERK1/2-MAPK, JNK1/2-MAPK, 
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PKCƐ-isoform, signal transducer and activator of transcription (STAT) 3, STAT-5, and 
protein kinase B (Akt) [23, 114, 120, 128, 295]. In mice, pigs, and humans it has been 
shown that episodes of blood pressure cuff inflation and deflation in an extremity 
increases the circulating NO and nitrite in the blood [148, 220, 221].     
 
1.5 Role of Cx43 in cardioprotection by preconditioning (PC) 
Preconditioning (PC) reduces the dephosphorylation of Cx43 caused by ischemia 
leading to reduction of electric uncoupling and HC opening [134, 186, 241]. The 
preserved phosphorylation of Cx43 during IPC is likely to be linked to increased 
activity of PKC and p38 [241], as well as decreased association to protein 
phosphatases [274]. However, pretreatment with heptanol, a GJ uncoupling agent, 
blocks IPC suggesting that Cx43 is essential for the signal transduction cascade of 
IPC’s cardioprotection [162]. Supporting evidence of Cx43’s role in cardioprotection 
came from experiments with heterozygous Cx43-deficient mice, in which 
cardioprotection by IPC was lost [244, 245]. Surprisingly, in isolated cardiomyocytes 
of Cx43-deficient mice, IPC induced cardioprotection was also abolished, suggesting 
a role of Cx43 in cardioprotection independent from GJs [167].             
While Cx43 is located at the sarcolemma (GJs and HC), it is also present in 
cardiomyocyte subsarcolemmal mitochondria (SSM), but not in interfibrillar 
mitochondria (IFM) which are present between myofibrils [24, 28, 231]. These two 
distinct subpopulation of mitochondria differ, besides their localization, in their 
morphology and function [229]. Evidence for the presence of Cx43 in mouse, rat, pig, 
and human left ventricle mitochondria was demonstrated by fluorescence-activated 
cell sorting, Western blot analysis, as well as confocal and electron microscopy [24]. 
Cx43 is imported via the regular mitochondrial import machinery, which was 
demonstrated by co-immunoprecipitation studies showing interactions of Cx43 with 
the translocase of the outer membrane 20 (TOM20) and heat shock protein 90 [230]. 
Following IPC, the amount of mitochondrial Cx43 (mtCx43) was rapidly increased 
and the increased amount was stable for the following 90 minutes. Evidence for the 
cardioprotective relevance of mtCx43 is attested by inhibition of the import of Cx43 
into mitochondria, attenuating diazoxide-induced cardioprotection [230]. In vitro 
cross-linking studies on mitochondria showed complexes of a molecular weight 
comparable with that of Cx43 hemichannels [184]. Supporting this notion, the two 
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hemichannel blockers carbenoxolone and heptanol reduced mitochondrial uptake of 
Lucifer Yellow dye [184]. In addition, mitochondrial ADP stimulated complex 1 
respiration was reduced by inhibiting Cx43-formed channels with mimetic peptides, 
by 18α-glycyrrhetinic acid (18αGA), or genetic modification of Cx43. Furthermore, in 
Cx43 overexpressing HL-1 cells, mitochondrial oxygen consumption was significantly 
increased [26].  
The main source of ROS production is the flavin mononucleotide site of complex 1 
and the Q cycle of complex III [6, 43, 190, 276]. Excessive ROS production leads to 
cell death, whereas moderate ROS formation contributes to cardioprotection. 
MitoKATP channels in the inner mitochondrial membrane have a regulatory effect on 
ROS production and K+ influx caused by opening of mitoKATP channels and 
subsequent ROS formation are considered to mediate cardioprotection [26, 184, 
200]. Mitochondrial ROS formation mediates signal transduction via redox-based 
post-translational protein modifications. 
In permeabilized cardiomyocytes achieved from wild type mice, in astrocytes, and in 
isolated mitochondria from mouse left ventricles, the application of Cx43 inhibitors 
18αGA and carbenoxolone reduced mitochondrial K+ uptake [29, 152]. Additional 
studies showed that replacement of Cx43 by Cx32 also led to decreased 
mitochondrial K+ influx, confirming a modulatory role of Cx43 in regulating 
mitochondrial K+ fluxes [108, 184]. Diazoxide-induced generation of ROS was 
reduced in Cx43 deficient cardiomyocytes, whereas valinomycin, a potassium 
ionophore, and menadione produced equal amounts of ROS in wild type and Cx43 
deficient cardiomyocytes and afforded subsequent cardioprotection. Thus, mtCx43 
appears to be an essential part of the signal transduction cascade of endogenous 
cardioprotection [20, 103, 115, 205].  
 
1.6 NO in cardioprotection  
NO and its metabolites have a cardioprotective impact and reduce ischemia/ 
reperfusion injury [58, 63, 79, 173, 183, 254]. Following IPC, SNO of sulfhydryl 
residues for a wide spectrum of proteins was found to be significantly increased 
[150]. Interestingly, studies identified S-nitrosothiols in mitochondria following IPC, 
attesting SNO’s influence on mitochondrial function and mitochondrial derived 
cardioprotection. Furthermore, SNO of proteins correlates with prevention of cell 
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death following prolonged ischemia and reperfusion [53, 191, 212, 263], and the 
reversible post-translational modification shielding cysteine from potential oxidation 
by ROS is thought to be the underlying protective mechanism [264, 266, 302]. ROS 
induced protein modifications are mainly irreversible, altering the function of proteins 
or even denaturing them. Thus increased ROS production during 
ischemia/reperfusion injury can lead to sustained myocardial dysfunction [307]. 
Therefore, the amount of SNO plays a critical role during ischemia/reperfusion injury.  
 
 
 
 
In the myocardium NO is synthesized by three different isoforms of nitric oxide 
synthase (NOS) [305], including neuronal NOS (NOS1), inducible NOS (NOS2), and 
endothelial NOS (NOS3). NOS1 and NOS3 are constitutively expressed [12], whereas 
the inducible isoform NOS2 is expressed following stress or pathological conditions 
[7]. In addition, NO can be generated independently from NOS by reduction of nitrite 
in a non-enzymatic manner [147, 177]. Treatment with NO donors like S-
nitrosoglutathione leads to increased SNO of proteins and cardioprotection [263]. NO 
is also involved in cardioprotective signaling [119, 263] and NO´s role in post-
translational modification of proteins has been increasingly recognized in recent 
years [240, 247, 264], especially during endogenous cardioprotective interventions 
[150]. Therefore, the balance between ROS and NO is essential for the regulation of 
Figure 1.5: Schematic display of protection by NO. Increased ROS formation during 
ischemia/reperfusion injury causes to irreversible cysteine oxidation (Ox) and 
myocardial dysfunction (left). Conversely, IPC increases SNO of proteins leading to 
cardioprotection by shielding cysteine residues from oxidative stress (right) [modified 
from Kohr et al., 2011].  
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cardioprotection. SNO has been shown to play an important role in the regulation of 
metabolism, signal transduction, and the regulation of myocardial key proteins. NO 
has a cyclic guanosine monophosphate (cGMP)-dependent and cGMP-independent 
effect on final target proteins. The cGMP-dependent pathways are regulated by NO 
modification of guanylate cyclase, which increases cGMP levels thereby regulating 
downstream cGMP-dependent kinases like PKG, which transmits cardioprotective 
signals to the mitochondria [63, 137, 303]. CGMP-independent pathways are directly 
regulated by SNO of proteins [105, 118, 178]. Among the target proteins which are 
regulated by SNO is the L-type Ca2+ channel [265], the sarcoplasmic reticulum Ca2+ -
ATPase [263], and the sarcoplasmic Ca2+ release channel [99, 286]. SNO also 
decreases the activity of mitochondrial proteins such as cytochrome c oxidase [301], 
F1F0ATPase [263], cyclophilin D [197], and mitochondrial complex 1 [54]. The NO 
donor 2,2′-(hydroxynitrosohydrazino)-bis-ethanamine inhibits the respiratory complex 
IV (cytochrome C oxidase) after long-term exposure in pulmonary artery endothelial 
cells, which is likely to be responsible for NO toxicity in lung endothelial cells [301]. A 
study showed that cardioprotection induced by IPC or by application of GSNO 
decreased F1-ATPase α1 subunit activity leading to a slower decline of ATP following 
prolonged ischemia [263]. Cyclophilin D mediates MPTP opening, which is reduced 
by application of the NO donor GSNO in wild type, but not in Cyclophilin D deficient 
mouse embryonic fibroblasts [197]. Application of a selective mitochondrial SNO 
donor inhibits mitochondrial complex 1 activity during the first 5 minutes of 
reperfusion in ischemic tissue, thereby protecting from oxidative damage by 
decreasing ROS production [54]. Additional SNO of proteins has been identified, 
among them are aconitate hydratase, aldehyde dehydrogenase, α-ketogluterate 
dehydrogenase, creatine kinase, malate dehydrogenase, and thioredoxin [53, 149, 
263]. Therefore, application of NO donors provides cardioprotection and reduces 
infarct size following ischemia/reperfusion injury with SNO of proteins being essential 
for cardioprotection. However, the full range of SNO targeted proteins, that influence 
myocardial function or those have a cardioprotective role have not been yet identified.  
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1.7 Aim of study  
The present investigation’s goal is to characterize the role of connexin 43 in 
mitochondrial function. Nitric oxide and mitochondrial connexin 43 play a role in the 
signal transduction cascade of cardioprotection. Since SNO regulates Cx43 at the 
sarcolemma, the question arises whether or not S-nitrosation regulates mitochondrial 
connexin 43 as well. Therefore, it is of interest if S-nitrosation of mitochondrial 
connexin 43 alters mitochondrial ion fluxes and generation of reactive oxygen 
species, since mitochondrial potassium fluxes and moderate increased formation 
reactive oxygen species are important for cardioprotection by preconditioning. The 
exact mechanism of how mitochondrial connexin 43 mediates ischemic 
preconditioning is unclear. Activation of the signal transduction cascade of ischemic 
preconditioning influences the posttranslational modification of several mitochondrial 
proteins. Thus, it is of interest whether or not S-nitrosation of mitochondrial connexin 
43 is increased following ischemic preconditioning, remote ischemic preconditioning, 
or application of nitric oxide donors. Addressing these questions would elucidate a 
missing link in the signal transduction cascade of cardioprotection by ischemic 
preconditioning. Furthermore connecting nitric oxide and mitochondrial connexin 43 
to the signal transduction cascade of cardioprotection would identify a potential 
pharmacological target that could reduce the damage of a myocardial infarct in 
patients suffering from pre-infarction symptoms. 
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2. Materials and Methods 
2.1 Materials  
2.1.1 Chemicals  
Acetone       Callbiochem, La Jolla, CA, USA 
Acetonitrile (ACN)      Callbiochem, La Jolla, CA, USA 
Adenosine-diphosphate     Sigma-Aldrich, Heidenheim 
Albumin standard   Thermo Fisher Scientific Inc., 
Darmstadt   
Ammonium carbonate (NH4CO3)   Callbiochem, La Jolla, CA, USA 
Amplex UltraRed reagent  Thermo Fisher Scientific Inc., 
Darmstadt   
Antimycin A      Sigma-Aldrich, Heidenheim  
Ascorbate       Sigma-Aldrich, Heidenheim  
N-(biotinyl)-N-(iodoacetyl)ethylenediamine  
(BIAM)      Sigma-Aldrich, Heidenheim 
Blotting grade blocker non-fat dry milk  Bio-Rad, Munich 
Bovine serum albumin     Sigma-Aldrich, Heidenheim  
Bis(sulfosuccinimidyl)suberate (BS3)  Life Technologies, Darmstadt  
Calcium chloride (CaCl2)    Roth, Karlsruhe 
Carbenoxolone      Sigma-Aldrich, Heidenheim  
Coomassie Brilliant Blue R-250   Sigma-Aldrich, Heidenheim 
Complete Protease Inhibitor (EDTA free)  Roche Diagnostics, Grenzach   
Cyclosporine A (CsA)    Sigma-Aldrich, Heidenheim  
D-glucose       Roth, Karlsruhe 
Dimethyl sulfoxide (DMSO)   Sigma-Aldrich, Heidenheim  
Disodium phosphate (Na2HPO4)   Roth, Karlsruhe 
Dithiothreitol (DTT)     Pierce, Rockford , IL, USA   
Dynabeads Protein G DynaMagTM  Thermo Fisher Scientific Inc., 
Darmstadt   
DyeLight maleimide sulfhydryl-reactive dyes  Pierce Biotechnology, Rockford, IL, 
USA 
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Ethanol       Merck, Darmstadt  
Ethylene diamine tetra acetic acid (EDTA) Roth, Karlsruhe 
Ethylene glycol-bis(β-aminoethyl ether)-  
tetraacetic acid (EGTA)     Sigma-Aldrich, Heidenheim 
Formic acid       Merck, Darmstadt  
Glibenclamide      Sigma-Aldrich, Heidenheim  
L-Glutamatic acid potassium salt   Sigma-Aldrich, Heidenheim   
Glycine      AppliChem, Darmstadt  
Gramicidin       Invitrogen, Darmstadt  
HEPES       Roth, Karlsruhe 
Horseradish peroxidase (HRP)   Roche Diagnostics, Grenzach  
Hydrogen chloride (HCl)    Merck, Darmstadt 
Hydrogen peroxide (H2O2)    Roche Diagnostic, Grenzach  
Isoflurane       Forane®, Abott GmbH, Wiesbanden 
Ketanest S      Pfitzer, Münster   
Lucifer Yellow CH dilithium salt    Sigma-Aldrich, Heidenheim  
Magnesium chloride (MgCl2)    Roth, Karlsruhe 
Magnesium sulfate (MgSO4)    Roth, Karlsruhe 
Malate      Sigma-Aldrich, Heidenheim  
Methanol       Roth, Karlsruhe 
3-(N-morpholino)propanesulfonic acid  
(MOPS)      Sigma-Aldrich, Heidenheim 
Neocuproine      Sigma-Aldrich, Heidenheim  
N-ethylmaleimide (NEM)    Sigma-Aldrich, Heidenheim  
Sodium nitrite (NaNO2)     Sigma-Aldrich, Heidenheim  
NuPAGE transfer buffer (20x)   Life Technologies, Darmstadt 
Oligomycine       Sigma-Aldrich, Heidenheim   
Percoll       GE Healthcare, Solingen  
Phosphatase inhibitor     Roche Diagnostics, Grenzach  
Pluronic® F127      Invitrogen, Darmstadt   
Ponceau S solution for electrophoresis   Serva, Heidelberg  
Potassium-binding benzofuran isophthalate 
acetoxymethyl ester (PBFI-AM)    Life Technologies, Darmstadt  
Potassium chloride (KCl)    Roth, Karlsruhe 
16  Materials and Methods 
Potassium dihydrogen phosphate (KH2PO4) Merck, Darmstadt  
Proteinmarker Precision Plus ProteinTM BioRad, Munich 
Rhodamine B-Isothiocyanate-dextrane     
(RITC-dextrane)     Sigma-Aldrich, Heidenheim 
Rompun      Bayer, Leverkusen  
Rotenone      Sigma-Aldrich, Heidenheim 
Sodium dodecyl sulfate (SDS)    Roth, Karlsruhe 
S-nitrosoglutathione (GSNO)   Santa Cruz, Heidelberg  
S-nitroso-N-acetyl-DL-penicillamine (SNAP) Life Technologies, Darmstadt  
Sodium-binding benzofuran isophthalate  
acetoxymethyl ester (SBFI-AM)   Life Technologies, Darmstadt  
Sodium bicarbonate (NaHCO3)   Roth, Karlsruhe 
Sodium carbonate (Na2CO3)   Roth, Karlsruhe  
Sodium chloride (NaCl)    Roth, Karlsruhe 
Sodium hydroxide (NaOH)   Roth, Karlsruhe 
Sodium phosphate (NaH2PO4)   Sigma-Aldrich, Heidenheim   
Streptavidin-agarose beads    Sigma-Aldrich, Heidenheim  
Succinate        Sigma-Aldrich, Heidenheim 
Sucrose      MP Biomedicals, Eschwege  
Tetraethylammonium chloride (TEA-Cl)  Sigma-Aldrich, Heidenheim  
Tetramethylammonium chloride (TMA-Cl) Sigma-Aldrich, Heidenheim  
Tris-Base       Merck, Darmstadt  
Tween-20       AppliChem, Darmstadt  
Urea        Sigma-Aldrich, Heidenheim   
Valinomycin      Sigma-Aldrich, Heidenheim 
XT Reducing agent (20x)    Bio-Rad, Munich  
XT Sample buffer (4x)    Bio-Rad, Munich 
 
 
 
 
 
Materials and Methods  17 
 
 
2.1.2 Antibodies and enzymes  
 
 
Antibody Distributor Dilution 
Rabbit polyclonal anti-rat connexin 43 
Sigma-Aldrich (C6219), 
Heidenheim 
1:1000 
Mouse monoclonal anti-rat 
sodium/potassium (Na+/K+)-ATPase α-1 
Millipore (# 05-369), 
Temecula, CA, USA 
1:500 
Mouse monoclonal anti-dog sarcoplasmic 
calcium 2 (SERCA2)-ATPase 
Sigma-Aldrich (S1314), 
Heidenheim 
1:500 
Rabbit monoclonal anti-human histone 
deacetylase 2 (HDAC2), clone Y461 
Millipore (# 04-229), 
Temecula, CA, USA 
1:500 
Mouse monoclonal anti-rabbit Glycer-
aldehyde-3-phosphate dehydrogenase 
(GAPDH) 
Hytest (# 5G4), Turku, 
Finland 
1:5000 
Rabbit polyclonal anti-human translocase of 
the outer membrane 20 (Tom20) 
Santa Cruz (sc-11415), 
Santa Cruz, CA, USA 
1:2000 
Rabbit polyclonal anti-human voltage-
dependent anion channel (VDAC) 
Abcam (ab34726), 
Cambridge, UK 
1:1000 
Rabbit polyclonal anti-human manganese 
dismutase (MnSOD) 
Millipore (# 06-984), 
Temecula, CA, USA 
1:2000 
Rabbit anti-phospho-connexin43 (S368) Cell Signaling (# 3511), 
Leiden, Netherlands 
1:1000 
Rabbit anti-phospho-connexin43 (S365) and 
rabbit anti-phospho-connexin43 (S373) 
prepared by Paul Lampe 
Lab, Fred Hutchinson 
Cancer Research Centre, 
USA [257] 
1:500 
Goat anti-rabbit IgG, HRP linked 
Cell Signaling (# 7074), 
Leiden, Netherlands 
1:5000 
Horse anti-mouse IgG, HRP linked 
Cell Signaling (# 7076), 
Leiden, Netherlands 
1:5000 
 
 
 
Table 2.1: Used primary and secondary antibodies 
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Nargase protease      Sigma-Aldrich, Heidenheim  
GAP26, Connexin Mimetic peptide  
(VCYDQAFPISHIR)     AnaSpec, Seraing, Belgium 
2.1.3 Kits  
Lowry assay: BioRad DC Protein Assay  BioRad, Munich  
Chemiluminescent substrate Pico   Healthcare Life Sciences, Freiburg  
Chemiluminescent substrate Femto   Healthcare Life Sciences, Freiburg  
 
2.1.4 Buffer and solutions  
Physiological saline  Braun Melsungen AG, Melsungen    
Isolation buffer   250 mM sucrose, 10 mM HEPES, 1 
mM EGTA, pH 7.4 adjusted with Tris-
base 
30% Percoll solution  30% Percoll (sterile filtered) in 
Isolation buffer 
Krebs-Henseleit buffer  120 mM NaCl, 11, mM D-glucose, 25 
mM NaHCO3, 1.75 mM CaCl2, 4.7 mM 
KCl, 1.2 mM MgSO4, and 1.2 mM 
KH2PO4, pH 7.4 adjusted with 95% 
O2/CO2  
Phosphate buffered saline (PBS)  pH 7.4, Merck Millipore, Schwalbach    
 
Buffers used for biochemical methods: 
Cell lysis buffer 10% cell lysis buffer (10x), 10% 
”Complete” protease inhibitor mix 
(10x) 
HEPES buffer   250 mM HEPES-NaOH, 1 mM EDTA, 
and 0.1 mM neocuproine, pH 7.7   
RIPA lysis buffer   Invitrogen, Grand Island, NY, USA 
 
Buffers used for precipitation:     
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Conjugate buffer  20 mM NaH2PO4, 0.15 M NaCl, pH 7-9  
Quenching buffer  1 M Tris-HCl 
IP buffer  PBS with 0.05% Tween-20 
 
Buffers used for SDS-PAGE and Western blot:  
MOPS buffer  20x MOPS buffer  
Comaisse blue staining  0.1% Coomassie Brilliant Blue R-250, 
50% methanol, and 10% glacial acetic 
acid 
Transfer buffer 20x NuPAGE Tranfer buffer, 10% v/v 
methanol 
 
Buffers used for antibody detection:  
Blocking solution   5% w/v blotting grade blocker non-fat 
dry milk in TBST 
TBS  10 mM Tris, 150 mM NaCl, pH 7.6 
TBST  0.1% Tween-20 in TBS  
 
Buffers used for proteomic analyses:   
Reduction solution  10 mM DTT, 25 mM NH4CO3 
Alkylation solution  25 mM NEM in 25 mM NH4CO3, 1 mM 
EDTA  
Washing buffer      25 mM NH4CO3 in 50% v/v ACN 
Trypsin solution     12.5 ng/µl in 25 mM NH4CO3, 1 mM 
EDTA 
 
Buffers used for analysis of mitochondrial function : 
Incubation buffer 125 mM KCl, 10 mM MOPS, 1.2 mM 
KH2PO4, 1.2 mM MgCl2, 20 µM EGTA, 
pH 7.4 
Isosmotic potassium buffer   150 mM KCl, 7 mM NaCl, 2 mM 
KH2PO4, 1 mM MgCl2, 6 mM MOPS, 6 
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mM succinate, 0.25 mM ADP, 0.5 µM 
rotenone, pH 7.2  
Glutamate/Malate buffer  5 mM glutamate, 2.5 mM malate in 
incubation buffer  
Succinate buffer   5 mM succinate, 2 µM rotenone in 
incubation buffer 
TEA buffer  120 mM TEA-Cl, 10 mM HEPES, 10 
mM succinate, 5 mM KH2PO4, 0.1 mM 
EGTA, 0.5 mM MgCl2, 5 µM rotenone, 
0.67 µM oligomycin, pH 7.2 
 
TMA buffer  120 mM TMA-Cl, 10 mM HEPES, 10 
mM succinate, 5 mM KH2PO4, 0.1 mM 
EGTA, 0.5 mM MgCl2, 5 µM rotenone, 
0.67 µM oligomycin, pH 7.2  
 
2.1.5  Consumables   
10% Bis-Tris SDS-Gels     Life Technologies, Darmstadt  
C18 column ZipTip      Millipore, Billerica, MA, USA 
PicoFrit analytical column New Objective, Woburn, MA, 
USA  
Protran® nitrocellulose transfer membrane (0.2 µm) Whatman, GE Healthcare, 
Solingen  
Zorbax 300SB-trap column  Agilent Technologies, Santa 
Clara, CA, USA 
 
2.1.6  Equipment  
AllegraTM 64R Centrifuge 
Centrifugal evaporator  
Clary Eclipse spectrophometer 
Digital sonifier 450 D Branson 
Beckman Coulter, Krefeld   
Heraeus, Hanau   
Varian, Mulgrave, Australia  
Emerson Technologies, 
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Dry Block DB-2D 
 
Electrophoresis power supply – EPS 601 
ELISA microplate reader model 680 
Laser Doppler Perfusion Imaging (LDPI) 
LTQ Orbitrap Velos mass spectrometer  
with Eksigent nanoLC-Ultra 1D plus system 
Oxygen meter 782 
pH 211R Microprosser pH meter 
Proteome Discover 1.1 
 
Typhoon 9400 variable mode imager 
 
Vascular occluder (6 mm) 
Ventilator side port Inspira 
 
X Cell SureLock Novex mini 
X Cell Blot Module 
Dietzenbach 
Techne, Burlington Township, NJ, 
USA 
GE Healthcare, Solingen    
Bio-Rad, Munich 
Perimed, Stockholm, Schweden 
Thermo Fisher Scientific, San 
Jose, CA, USA 
Strahtkelvin, Glasgow, UK 
Hanna Instruments, Kehl   
Thermo Fisher Scientific, San 
Jose, CA, USA 
GE Healthcare Lifesciences, 
Piscataway, NJ, USA 
Kent Scientific, Torrington, USA 
Harvard Apparatus, Hugo-Sachs, 
March-Hugstetten 
Invitrogen, Darmstadt 
Invitrogen, Darmstadt 
 
2.2 Methods 
2.2.1 Animals  
All rodents were treated according to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH publication no. 85-23, 
revised 1996) and approved by the Institutional Laboratory Animal Care and Use 
Committee of the NIH, Bethesda, MD, USA or according to the European Convention 
for Protection of Vertebrate Animals Used for Experimental and Other Scientific 
Purposes (Council of Europe Treaty Series No. 123). For Langendorff heart perfusion 
experiments male Sprague-Dawley rats (190–210 gram and 7-8 weeks old) were 
anesthetized with pentobarbital and anti-coagulated with heparin. Male Wistar-
Janvier rats (190-210 gram and 8–10 weeks old) were used for mitochondrial 
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permeability experiments and were anesthetized with 2.5% v/v isoflurane. Male 
C57BL/6J mice used for rIPC studies were 11–14 weeks of age with a body weight 
ranging from 25–35 gram. They were anesthetized by intra peritoneal (i.p.) injection 
of ketamine (45 mg/kg) and xylazine (Rompun, 10 mg/kg) according to their body 
weight. The performed animal experiments were authorized (TVA Nummer: 
G347/12).   
 
2.2.2 Isolation of mitochondria  
All procedures were performed at 4°C to maintain mitochondrial integrity. To prevent 
light-induced SNO breakdown, samples were kept in the dark during the isolation 
process. SSM were isolated from left ventricles of male rats or mice as described 
previously [24]. For functional analysis, the left ventricles of rat hearts were minced in 
isolation buffer, homogenized with an Ultra Turrax and centrifuged at 800 g for 10 
minutes. The resulting supernatant was centrifuged for 10 minutes at 12,200 g and 
the pellet was resuspended in BSA-free isolation buffer and centrifuged twice at 
10,300 g for 5 minutes.     
IFM, which lack Cx43, were used as negative controls and isolated as previously 
described [28]. The hearts were weight; left ventricles were minced, homogenized 
and centrifuged at 800 g for 10 minutes. The resulting pellet was resuspended ) and 
incubated on ice for 1 minute in 5 ml isolation buffer additional containing 0.5% BSA 
and nargase (8 U/g. The tissue was homogenized and centrifuged at 800 g for 10 
minutes and the supernatant was centrifuged for 10 minutes at 12,200 g. The 
resulting pellet was resuspended in BSA free isolation buffer and centrifuged twice at 
10,300 g for 5 minutes.      
For quantitative SNO analysis, a BSA-free isolation buffer supplemented with 0.1 mM 
neocuproine, EDTA free complete protease inhibitor, and phosphatase inhibitor was 
used. The mitochondria were isolated as described above from rodent left ventricles. 
The right ventricles were frozen at -80°C and were used as control. The isolated 
mitochondria from left ventricles were layered on a 30% Percoll gradient and 
centrifuged for 30 minutes at 35,000 g. This resulted in a lower fraction containing 
pure SSM and an upper fraction containing cell debris. The lower fraction was 
collected and washed three times with isolation buffer by centrifuged at 10,200 g for 5 
minutes.  
Materials and Methods  23 
 
 
Protein concentrations were determined by the Lowry assay using BSA as a 
standard. For quantitative analysis the purity of isolated mitochondria was validated 
by Western blot analysis confirming the absence of non-mitochondrial cellular 
proteins (Na+/K+-ATPase, SERCA2a, HDAC2, and GAPDH) and the enrichment of 
mitochondrial proteins (VADC, MnSOD, and TOM20). Mitochondria were stored at    -
80°C.  
 
2.2.3 Analyses of mitochondrial membrane potential 
A toxic effect of carbenoxolone on mitochondria was analyzed by measuring the 
membrane potential. A loss of membrane potential indicated MPTP opening or 
membrane rupture. Mitochondria (0.5 mg/ml) were added to isolation buffer 
supplemented with 5 mM NaCl and 100 nM rhodamine 123 dye. The rhodamine 123 
dye accumulates in membranes in a membrane potential dependent manner. After 
measuring the fluorescence (λex 503 nm; λem 535 nm) for 3 minutes with a stable 
mitochondrial membrane potential DMSO, 1 µM, 25 µM, or 35 µM Carbenoxolone 
were added. A toxic effect is characterized by an increase of fluorescence intensity 
indicated by a release of membrane accumulated dye caused by a loss of membrane 
potential.    
 
2.2.4 Measurements of mitochondrial autofluorescence  
Mitochondrial autofluorescence was measured by using NADPH (λex 340 nm; 
λem 460 nm) as a fluorescence indicator for mitochondrial integrity. For testing 
carbenoxolone toxicity, 1 mg SSM was applied after 30 seconds measuring the level 
of baseline fluorescence in 2 ml isolation buffer. Then, after measuring mitochondrial 
autofluorescence for 3 minutes DMSO, 1 µM, 25 µM, or 25 µM carbenoxolone was 
applied. A decline of mitochondrial autofluorescence indicates a mitochondrial loss of 
NADPH due to MPTP opening or membrane rupture.  
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2.2.5 Dye permeation experiments  
Dye permeation experiments were performed according to Miro-Casas et al. [184]. 
Freshly isolated mitochondria were pelleted by centrifugation at 10,200 g for 3 
minutes at 4°C and resuspended at a concentration of 400 µg/ml in isosmotic 
succinate buffer. Mitochondria were assigned to groups either supplemented with 1 
µM, 10 µM, or 25 µM of the hemichannel blocker carbenoxolone, 0.5 mM NO donor 
S-nitroso-N-acetyl-DL-penicillamine (SNAP), 1 mM of NO donor S-nitrosoglutathione 
(GSNO), a combination of NO donor and carbenoxolone, or 5 µl DMSO. Additional 
mitochondria from Langendorff perfused hearts receiving IPC or that were control 
perfused were assigned to dye permeation experiments. As a control, IPC receiving 
or control mitochondria were exposed to UV light for 5 minutes to remove light 
sensitive SNO modifications. After a 5 minute incubation period at 25°C and 650 rpm, 
50 µM of the Cx43 hemichannel-permeable dye Lucifer Yellow CH dilithium salt (LY) 
and 25 µg/ml of the hemichannel-impermeable dye rhodamine B isothiocyanate-
dextran 10S (RITC-dextran) were added and samples were incubated for 25 minutes 
at 25°C and 650 rpm. Subsequently, mitochondria were washed and resuspended in 
200 µl succinate buffer. Fluorescence of LY (λex 430 nm; λem 535 nm) and RITC-
dextran (λex 545 nm; λem 600 nm) was measured by a 96-microplate fluorometer at 
high sensitivity. As a negative control, experiments were performed with ultrasound 
treated (20 seconds, amplitude 50%) mitochondria to exclude interference of dye and 
membrane fragments, as well as with IFM to confirm Cx43 hemichannel-specific 
effects. 
   
2.2.6 Mitochondrial potassium uptake         
Experiments for measuring velocity of mitochondrial K+ influx were modified from 
Miro-Casas et al. [184]. Freshly isolated mitochondria were resuspended at a 
concentration of 400 µg/ml in isolation buffer. Either 1 µM, 10 µM, or 25 µM 
carbenoxolone, 0.5 mM SNAP, the combination of both, or 5 µl DMSO was added to 
mitochondria and incubated for 20 minutes at 25°C and mixed at 650 rpm. The 
experiments were repeated with the use of 1 mM physiologically relevant NO donor 
GSNO instead of SNAP. Subsequently, mitochondria were loaded with 10 µM 
acetoxymethyl of potassium-binding benzofuran isophthalate (PBFI) for 10 minutes at 
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25°C and 650 rpm. The benzofuran isophthalate derivatives with their cell-permeant 
acetoxy methyl (AM) are able to permeate mitochondria. Once inside the 
mitochondria the lipophilic AM group is cleaved by unspecific esterases, resulting in a 
charged form of the potassium indicator, which is not able to pass mitochondrial 
membranes. K+ depletion from the mitochondrial matrix was achieved by adding 3 
volumes of tetraethylammonium (TEA) buffer, which replaces K+ in the mitochondrial 
matrix. Subsequently, mitochondria were washed, sedimented at 10,200 g and 4°C 
for 3 minutes, and resuspended in 30 µl isolation buffer. The kinetics of mitochondrial 
K+ uptake were measured after a KCl pulse of 140 mM at alternated excitations at 
340/380 nm and emission at 500 nm by a fluorometer in 2 ml isolation buffer at 
medium sensitivity. In order to measure the K+ permeability for the Cx43 hemichannel 
only, during measurements, MPTP opening was blocked by adding 1 µM CsA  [110], 
the proton channel of the ATP-synthase was blocked with 1µg/ml oligomycin, and 
opening of ATP-dependent potassium channels was blocked by 5 µM glibenclamide 
[246, 267]. The experiments were repeated without these inhibitors to investigate the 
influence of NO donors on the K+ influx under physiological conditions. The K+ influx 
during the first 2 seconds after the KCl-pulse, was determined by the increase of the 
PBFI fluorescence ratio of 340/380 nm per second in different treatment groups. As a 
positive control, K+ influx was determined after addition of 5 nM valinomycin, which is 
highly sensitive to sodium and potassium and functions as a sodium and potassium 
specific transporter across membranes. In order to confirm a Cx43 specific effect, 
experiments were also performed with IFM instead of SSM.    
   
2.2.7 Mitochondrial sodium uptake    
Experiments for measuring the velocity of mitochondrial Na+ influx were performed 
similarly as measuring potassium influx. Mitochondria were treated either with 25 µM 
carbenoxolone, 0.5 mM SNAP, 1 mM GSNO, the combination of NO donor and 
carbenoxolone, or 5 µl DMSO and then loaded with 10 µM acetoxymethyl of sodium-
binding benzofur (SBFI) instead of using PBFI. Sodium depletion was then performed 
with tetramethylammonium (TMA) buffer. After subsequent washing, the kinetics of 
mitochondrial Na+ uptake were measured after a NaCl pulse of 10 and 140 mM at 
alternated excitations at 340/380 nm and emission at 500 nm by a fluorometer. This 
was performed in 2 ml isolation buffer as well as in 2 ml succinate buffer 
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supplemented with inhibitors for MPTP, ATP-synthase, and ATP-dependent 
potassium channels as described above at high sensitivity. Na+ influx of the first 2 
seconds after the NaCl-pulses was determined by the increase of the SBFI 
fluorescence ratio of 340/380 nm per second of the six different treated groups. As a 
positive control, Na+ influx was determined after addition of 5 nM gramicidin, which 
has a similar function as valinomycin and forms a channel for potassium and sodium, 
but does not interfere with SBFI dye as does valinomycin.   
  
2.2.8 ROS production  
One mg of freshly isolated SSM or IFM were added to 2 ml incubation buffer 
containing 5 mM glutamate and 2.5 mM malate as a substrate, 10 U/ml horseradish 
peroxidase (HRP), and 50 µM Amplex UltraRed reagent. Amplex UltraRed is a 
fluorogenic substrate for HRP that reacts with hydrogen peroxide (H2O2). For 
estimating the NO-mediated influence of mtCx43 on ROS production either 25 µM 
carbenoxolone, 0.5 mM SNAP, 1mM GSNO, a combination of a NO donor and 
carbenoxolone, or 20 µl dH2O was added 30 seconds before the measurement was 
started. Additional experiments were completed inhibiting Cx43 by using the Cx43 
mimetic peptide Gap26. Analysis of ROS formation was performed by a fluorometer 
at an extinction and emission wavelength of 568/581 nm. Mitochondrial H2O2 
production was measured for 4 minutes and the increase of H2O2 was expressed in 
nmol/min/mg protein by comparing the data to a standard curve estimated with H2O2. 
After 4 minutes of measurement, 2 µg/ml of mitochondrial complex III inhibitor 
antimycin A was added for inducing mitochondrial ROS overproduction, which served 
as a positive control. Furthermore experiments were repeated in presence of 30 nM 
FCCP or 2 µM of complx 1 inhibitor rotenone.  
 
2.2.9 Rat heart perfusion protocols  
Excised rat hearts were placed in ice-cold Krebs-Henseleit buffer and the hearts were 
Langendorff perfused in retrograde fashion with oxygenated Krebs-Henseleit buffer 
(95% O2/5% CO2, pH 7.4) at a constant pressure of 100 cm water at 37°C. Hearts 
were randomly assigned to either a control group perfused for 40 minutes under 
normoxic conditions or an ischemic preconditioned (IPC) group in which the hearts 
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were perfused for 20 minutes under normoxic conditions followed by four cycles of 5 
minutes ischemia and 5 minutes reperfusion [170, 263]. Perfusion was performed in 
the dark to prevent breakdown of SNO modifications. Control experiments were also 
performed by daylight confirming light sensitivity of SNO modifications.  
  
2.2.10  In vivo remote ischemic preconditioning  
The following method of the induction of cardioprotection by remote ischemic 
preconditioning or application of nitrite was performed by Dominik Semmler from the 
Cardiovascular Research Laboratories of the Heinrich Heine University Düsseldorf. 
C57BL/6J mice were anesthetized by i.p. injection of ketamine (45 mg/kg) and xylazin 
(Rompun 10 mg/kg) and a tracheal tube was inserted for mechanical ventilation, 
which was performed according to the individual body weight at a tidal volume of 2.1 - 
2.5 ml and a respiratory rate of 140 breaths per minute. The mice were supplemented 
with 100% oxygen via a rodent ventilator (Minivent) side port. Around the right upper 
hindlimb a small vascular occluder with internal inflation pressure of 200 mmHg (6 
mm), measured digitally, was used to arrest the hindlimb perfusion. The rIPC mouse 
model achieved 4 cycles of 5 minutes hindlimb ischemia followed by 5 minutes of 
reperfusion. The control group was perfused for 40 minutes. rIPC was stimulated by 
pharmacological preconditioning induced by injection of 48 nM nitrite into the cavity of 
the left ventricle, whereas the control group received an equal volume of 50 µl 
physiological saline. The chest was opened through a midline sternotomy. Mouse 
hearts were excised and mitochondria were isolated as described above.  
 
2.2.11  Labeling and precipitation of SNO modified proteins  
A modified biotin switch method was used for labeling and quantification of SNO 
protein modifications as previously described [133]. SSM protein samples (250 µg) 
and controls (250 µg IFM, and 250 µg right ventricle of hearts) diluted in HEPES 
buffer supplemented with EDTA free complete protease inhibitor, phosphatase 
inhibitor, 0.1 mM neocuproine, and 2.5% SDS (wt/vol), were pressed 5 times through 
a 27 gauge needle. To block free thiols, 50 mM N-ethylmaleimide (NEM) was used. 
After incubation for 20 minutes at 50°C with gentle mixing every 5 minutes, free thiols 
were labeled with NEM and could not be modified. This procedure was stopped by 
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removing NEM via cold acetone precipitation (-20°C). The samples were then 
resuspended in HEPES buffer with 1% SDS (wt/vol) containing 1 mM ascorbate for 
reduction of SNO modified cysteine residues. Reduced SNO groups were labeled 
with N-(biotinoyl)-N-(iodoacetyl)ethylenediamine (BIAM). Prior to incubating samples 
with streptavidin-agarose beads for precipitation of SNO modified proteins, 2 µl of 
loading control was taken. Precipitation was performed overnight with rotation at 4°C 
in the dark. Samples were washed three times with HEPES buffer, eluted in 30 µl 
sample buffer with 10 M urea and heated at 95°C for 5 minutes. Specificity of the 
biotin switch method was proven by adding 10 mM or 100 mM DTT before eluting the 
sample, which breaks the disulfide bound between the thiol group and biotin. Western 
blot analysis was subsequently performed. 
 
2.2.12  Analysis of NO donor impact on mtCx43 phosphorylation   
The influence of NO donors on mtCx43 phosphorylation was analyzed. Mitochondria 
were incubated either with 1 µM carbenoxolone, 0.5 mM SNAP, 1 mM GSNO, the 
combination of a NO donor and carbenoxolone, or 5 µl DMSO in incubation buffer. 
Subsequent mitochondrial purity was achieved by Percoll gradient centrifugation as 
described above. Phosphorylation of Cx43 was then investigated by Western Blot 
analysis was performed with Phospho-connexin 43 antibodies directed against serine 
residues Ser365, Ser368, and Ser373.   
  
2.2.13  Western blot analysis   
Right ventricles (RV) of hearts were minced and used as positive controls. All 
controls were diluted with RIPA lysis buffer or cell lysis buffer and centrifuged at 
13,000 g for 10 minutes at 4°C. Protein concentration of supernatants was estimated 
using the Lowry assay using BSA as a standard. Both mitochondrial samples and 
controls were separated by electrophoresis on 10% Bis-Tris SDS-Gels and 
transferred to nitrocellulose membranes. Protein transfer was controlled by 
membrane staining with Ponceau S. After blocking with 5% (w/v) nonfat dry milk, 
membranes were incubated with primary antibodies diluted according to product 
instructions in 5% (w/v) nonfat dry milk (see table 2.1). The corresponding IgG HRP-
conjugate combined with chemiluminescent substrate or corresponding DyLight 
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maleimide sulfhydryl-reactive dyes combined with fluorescence emission at 700 nm 
were used as secondary antibodies and scanned on a Typhoon 9400 variable mode 
imager.   
 
2.2.14  Precipitation of mtCx43 and SNO labeling for proteomic analysis  
Immunoprecipitation (IP) was performed for enriching proteins of interest for 
proteomic analysis. Five hundred µg SSM, from either IPC or control perfused rat 
hearts in HEPES buffer were supplemented with EDTA free complete protease 
inhibitor, phosphatase inhibitor, 0.1 mM neocuproine, and pressed 5 times through a 
27 gauge needle. Then samples were lysed by adding 2.5% SDS. Free thiols were 
labeled with NEM for 20 minutes at 50°C. After acetone precipitation, SNO 
modifications were reduced with ascorbate and labeled with 55 mM iodoacetamide. 
Polyclonal rabbit anti-Cx43 antibody was used for IP assays. Dynabeads Protein G 
DynaMagTM-2 was cross-linked to 5 µg antibody with bis(sulfosuccinimidyl)suberate 
(BS3) to reduce the antibody presence according to product instructions. Dynabeads 
(1.5 mg) were washed with conjugate buffer and incubated with 5 mM BS3 in 
conjugate solution with rotation for 30 minutes. Crosslinking reactions were quenched 
by adding 1 M Tris-HCl with rotation for 15 minutes. Dynabeads were washed three 
times with IP buffer supplemented with EDTA-free complete protease inhibitor, 
phosphatase inhibitor, and 0.1 mM neocuproine. Five µg of rabbit anti-Cx43 or 
negative control rabbit IgG1 were added and incubated for 30 minutes with rotation 
forming antibody-Dynabead complexes. After washing, 500 µg of SSM and IFM 
fraction samples or total homogenate was added and the mixture was incubated with 
rotation overnight at 4°C.  Samples were then washed 3 times with 200 µl PBS, 
eluted in 100 µl PBS, and added to new tubes. After discarding the supernatant, 
beads were resuspended in 30 µl XT Sample buffer with XT Reducing agent and 
proteins were eluted from beads by heating for 5 minutes at 95°C. Samples were 
then separated by SDS-gel electrophoresis. For visualizing protein bands SDS gels 
were Coomassie stained. After washing the gel with dH2O, the gel was stained by 
incubation for 20 minutes with Coomassie solution. Then the gel was washed 5 times 
with dH2O and destained with dH2O at 4°C overnight.    
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2.2.15  Identification of SNO cysteine residues by LC-MS/MS analysis  
The pretreatment of samples analyzed by mass spectrometrically analyses was 
performed by the author or by the research group of Prof. Dr. Lochnit from the 
biochemical institute of the Justus-Liebig University Giessen. Coomassie stained 
SDS gel bands of 43 kDa were cut out into small pieces to facilitate enzyme access. 
To remove the Coomassie dye and SDS traces, gel pieces were washed three times 
and incubated for 15 minutes with 25 mM NH4CO3 in 50% acetonitrile (ACN).  Traces 
of ACN were removed using a centrifugal evaporator for complete dryness. Gel 
pieces were rehydrated for one hour at 56°C in reduction solution. Resulting free 
thiols of peptides were blocked with an alkylating solution followed by incubation for 
45 minutes at room temperature in the dark. Gel pieces were then washed with 25 
mM NH4CO3 in 50% ACN and samples were dried via centrifugation by using a 
centrifugal evaporator. The gel pieces were then trypsinized and digestion was 
performed overnight at 37°C. The supernatants were transferred to new tubes and 
gel pieces were incubated twice for 15 minutes on ice with 0.1% formic acid in 50% 
ACN to extract the remaining protein. All supernatants were combined and 
concentrated via centrifugal evaporation to a volume of 10 µl. After adding 15 µl of 
0.1% formic acid, samples were cleaned with a C18 column. Liquid chromatography 
tandem MS (LC-MS/MS) was performed by Prof Dr. Günther Lochnit from the 
Biochemical Institute of the Justus-Liebig University or by Dr. Marian Gucek from the 
NIH in Bethesda, MD, USA using a LTQ Orbitrap Velos mass spectrometer coupled 
to an Eksigent nanoLC-Ultra 1D plus system that uses collision-induced dissociation 
(CID) fragmentation. Samples were loaded with a flow rate of 6 µl/minutes on to a 
Zorbax 300SB-trap column. Separation was performed using a reversed-phase 
PicoFrit analytical column with a 40 minutes linear gradient of 5–40% acetonitrile in 
0.1% formic acid at a flow rate of 250 nl/minutes. LTQ Orbitrap Velos settings were 
chosen as follows: spray voltage 1.5 kV, and full MS mass ranger of m/z 230-2,000. 
Analysis was implemented in a data-dependent mode with one MS1 high-resolution 
(60,000) scans for precursor ions, and six data-dependent MS/MS scan for precursor 
ions above the threshold ion count of 2,000 with collision energy of 35%. 
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2.2.16  MASCOT database analysis 
The LTQ Orbitrap Velos raw data output was analyzed with Proteome Discover 1.1 
(Thermo Fisher Scientific) with the NIH six-processor MASCOT cluster search engine 
(http://biospec.nih.gov, version 2.3) using the following criteria: database. Swiss-Prot 
(Swiss Institute of Bioinformatics); taxonomy, Rattus norvegicus (rat); enzyme, 
trypsin; miscleavages 3; variable modifications, NEM and iodoacetamide 
(carbamidomethyl); MS peptide tolerance 25 ppm, and MS/MS tolerance 0.8 Da. An 
ion score that measured if the MS/MS spectra matched the stated peptide was 
allocated. Ion scores were measured in 10 x log10 (P), representing the probability of 
a random match (expectation value). Therefore, a high score represents a confident 
match as described by Perkins et al. (1999).  
 
2.2.17  Statistics 
Data are presented as mean ± SEM. Normal distribution of data was analyzed using 
a non-parametric Kolmogorov–Smirnov test. Unpaired Student´s t test was used 
between the two groups of IPC and control mitochondria of Western blot data and 
dye permeation data to determine the difference in the mean values. Unpaired 
Student´s t tests were used between the two groups of IPC and control rat left 
ventricular mitochondria, as well as between rIPC and control mouse left ventricular 
mitochondria of Western blot data and dye permeation experiments. This was used to 
determine the difference in the mean values of SNO modifications of mtCx43 data 
between two groups. Data of LY, K+ uptake, Na+ uptake and ROS formation were 
compared by two-way repeated measures ANOVA and Fisher`s LSD. Statistical 
significance was determined at p<0.05. 
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3. Results 
NO plays a role in cardioprotection by preconditioning and is known to alter the 
function of several proteins involved in cardioprotective signaling. MtCx43 is part of 
the signal transduction cascade of preconditioning and regulates mitochondrial 
function. 
 
3.1 SNO of mtCx43 influences mitochondrial function  
It is of interest if SNO of mtCx43 plays a role in altering mitochondrial function. 
Mitochondrial function was analyzed by measuring mitochondrial permeability for 
dyes and specific ions, as well as mitochondrial ROS generation with exposure to 
either NO donors and/or Cx43-formed channel inhibitors. 
  
3.1.1 Estimation of carbenoxolone toxicity  
Carbenoxolone was used to reduce the open probability of Cx43-formed channels. 
To define the adequate concentration of carbenoxolone, its mitochondrial toxicity was 
analyzed. Loss of mitochondrial membrane potential or loss of mitochondrial auto-
fluorescence was used to indicate mitochondrial damage. Thus, the release of 
membrane potential dependent accumulated rhodamine 123 dye and the subsequent 
increase in fluorescence intensity was analyzed under exposure to concentrations of 
1 µM, 25 µM, 35 µM carbenoxolone, and DMSO used as a vehicle. The mitochondrial 
membrane potential was only lost in the presence of 35 µM carbenoxolone indicating 
a toxic effect of carbenoxolone solely at high concentrations (Figure 3.1). 
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Additional mitochondrial autofluorescence measurements were performed to analyze 
the toxic effect of carbenoxolone. Measurements were performed by using NADPH 
(λex 340 nm; λem 460 nm) as a fluorescence indicator for mitochondrial integrity. 
Application of 35 µM carbenoxolone rapidly decreased mitochondrial 
autofluorescence (Figure 3.2). Carbenoxolone concentrations of up to 25 µM, which 
were used in this study, had no effect on mitochondrial membrane potential and 
autofluorescence indicating the nontoxic effects of carbenoxolone used in this study.  
 
Figure 3.1: Analyses of carbenoxolone toxicity measuring mitochondrial membrane potential. 
Subsarcolemmal mitochondria (SSM) were loaded with rhodamine 123 dye, which accumulates in 
membranes in a membrane potential dependent manner. Mitochondria were applied to the 
rhodamine 123 containing solution after 90 seconds leading to decline of fluorescence intensity 
indicating mitochondrial dye uptake. Subsequently, after 210 seconds 1 µM, 25 µM, 35 µM 
carbenoxolone (CBX), or DMSO were administered. An increase of fluorescence intensity indicated 
loss of membrane potential (A). The difference of arbitrary units (a.u.) of fluorescence intensity 
before and after application of carbenoxolone are shown as means ± SEM of 3 replicates per group. 
* (p<0.05) indicates significant differences between groups (B).       
 
34  Results 
 
 
 
 
 
 
3.1.2 Analysis of NO’s impact on mitochondrial permeability    
Analyses of mitochondrial permeability were performed to investigate the influence of 
NO donors on mitochondrial function with and without inhibition of Cx43-formed 
channels. Rat mitochondria were treated either with 5 µl DMSO, 1 µM or 25 µM 
carbenoxolone, 0.5 mM SNAP, 1 mM GSNO, or a combination of a NO donor and 
carbenoxolone. Fluorescence analyses were performed after exposure to 50 µM LY 
and 25 µg/ml RITC-dextran (Figure 3.3). 
Figure 3.2: Analyses of carbenoxolone toxicity measuring mitochondrial autofluorescence. 
Subsarcolemmal mitochondria (SSM) were applied to cuvettes and fluorescence of NADPH 
(λex 340 nm; λem 460 nm) was measured after 30 seconds. After 210 seconds, 1 µM, 25 µM, 35 µM 
carbenoxolone (CBX), or DMSO was applied. The decrease of fluorescence intensity indicated loss of 
mitochondrial membrane integrity (A). The difference of arbitrary units (a.u.) of fluorescence intensity 
before and after application of carbenoxolone are shown as means ± SEM of 3 replicates per group. * 
(p<0.05) indicates significant differences between groups (B).       
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Mitochondrial LY fluorescence intensity was significantly increased after application 
of the NO donor SNAP compared to DMSO as control by 38.4 ± 9.3% (n=12, 
p<0.05). The increase in LY uptake was slightly lower in mitochondria treated with the 
NO donor GSNO, but still GSNO increased LY uptake by 28.1 ± 7.4% (n=12, p<0.05) 
compared to control. The NO-mediated increase in mitochondrial LY uptake was 
abolished in the presence of carbenoxolone, which at a concentration of 1 µM 
decreased LY uptake by 17.7 ± 2.9% compared to DMSO control (n=12, p<0.05), by 
36.7 ± 2.7% (SNAP + carbenoxolone versus SNAP; n=12, p<0.05) compared to 
SNAP, and by 33.4 ± 1.8% (GSNO + carbenoxolone versus GSNO; n=12, p<0.05) 
compared to GSNO treated SSM (Figure 3.4A). The fluorescence intensity of the HC 
impermeant dye RITC-dextran showed no difference throughout the different 
treatments (n=12, p=ns) (Figure 3.4B). A concentration of 25 µM carbenoxolone 
caused a similar decrease of LY uptake. The LY fluorescence intensity was reduced 
by 17.4 ± 5.9% (n=6, p<0.05) in mitochondria treated with 25 µM carbenoxolone 
compared to DMSO control (Figure 3.4C). Mitochondrial treatment with 
carbenoxolone at a concentration of 25 µM did not influence the measured 
fluorescence intensity of RITC-dextran (Figure 3.4D).  
Figure 3.3: Schematic display of experimental setup for measuring mitochondrial LY dye uptake.  
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The experiments were also performed with IFM instead of SSM. Experiments with 
IFM did not show an altered dye uptake between different treatment groups (n=7, 
p=ns) (Figure 3.5). Since IFM do not contain Cx43, these experiments support a 
Cx43 specific effect of increased permeability caused by SNO. 
 
Figure 3.4: LY dye uptake of SSM. SSM were treated either with 1 µM (A+B) or 25 µM (C+D) 
carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitrosoglutathione (GSNO), a 
combination of NO donor and hemichannel blocker (SNAP + carbenoxolone; GSNO + carbenoxolone), 
and dimethyl sulfoxide (DMSO; used as solvent). Dye uptake of the hemichannel permeable dye LY 
(A+C) and the hemichannel impermeable dye RITC-dextran (B+D) was measured and expressed as 
arbitrary units of fluorescence. Data are shown as mean ± SEM of 6–12 replicates per group from intact 
SSM. * (p<0.05) indicates significant differences versus marked groups.   
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Additionally, to exclude any false positive or false negative results by agent induced 
accumulation of LY in membrane fragments, the experiments were also performed 
with ruptured SSM. SSM received an ultrasound treatment, which ruptures the 
mitochondrial membranes. These studies with ultrasound treated mitochondria 
displayed no difference in LY uptake among different treated groups (n=7, p=ns). 
Also in this case fluorescence intensity of RITC-dextran did not differ between the 
different protocols (n=7, p=ns) (Figure 3.6).    
 
 
 
Figure 3.5: LY dye uptake of IFM. IFM were used as a negative control lacking Cx43. After treatment 
either with 1 µM carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-
nitrosoglutathione (GSNO), a combination of NO donor and hemichannel blocker (SNAP + 
carbenoxolone; GSNO + carbenoxolone), or dimethyl sulfoxide (DMSO; used as solvent), dye uptake 
of the hemichannel permeable dye LY (A) and the hemichannel impermeable dye RITC-dextran (B) 
was measured and expressed as arbitrary units of fluorescence. Data are shown as mean ± SEM of 7 
replicates per group of IFM from rat left ventricles (LVs).  
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3.1.3 Mitochondrial potassium uptake 
Mitochondria were incubated separately either with 1 µM, 10 µM, or 25 µM 
carbenoxolone, 0.5 mM SNAP, 1 mM GSNO, a combination of NO donor and 
carbenoxolone, or 5 µl DMSO used as a vehicle. The velocity of potassium (K+) influx 
into the matrix of mitochondria from rat left ventricles was estimated by measuring the 
increase of the 340/380 nm  fluorescence intensity ratio for 2 seconds after addition 
of a 140 mM KCl pulse. The potassium indicator PBFI consists of fluorophores linked 
to nitrogen of crown ether which confers selectivity to K+. Upon ion binding the 
excitation maxima of PBFI shifts to a shorter wavelength causing a change in ratio of 
energy absorbed at 340/380 nm. In order to measure the K+ permeability through 
Cx43 hemichannels, other mitochondrial channels including ATP-dependent 
potassium channels, ATP-synthase, and MPTP were blocked with glibenclamide, 
oligomycin, and cyclosporine A. Mitochondria treated with NO donors showed a 
significantly higher refilling rate of K+. The velocity of K+ uptake was 227.9 ± 30.1% 
higher in SNAP treated mitochondria compared to DMSO control (n=10, p<0.05). 
Figure 3.6: LY dye uptake of ultrasound treated SSM. SSM were either incubated with 
carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitrosoglutathione (GSNO), a 
combination of a NO donor and hemichannel blocker (SNAP + carbenoxolone; GSNO + 
carbenoxolone), or dimethyl sulfoxide (DMSO; used as solvent). After incubation with LY and RITC-
dextran mitochondria were ruptured by ultrasound. Possible dye interaction with membrane 
fragments were analyzed by measuring LY dye (A) and RITC-dextran dye (B), which were 
expressed as arbitrary units of fluorescence. Data are shown as mean ± SEM of 7 replicates per 
group of ultrasound treated mitochondria from rat LVs.   
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Application of the NO donor GSNO increased the velocity of K+ influx by 122.6 ± 
28.1% (n=7, p<0.05) compared to control. The NO mediated increases of 
mitochondrial K+ influx by SNAP and GSNO were significantly blocked by 
carbenoxolone at a concentration of 1 µM. With carbenoxolone application, velocity 
of K+ influx decreased by 153.2 ± 24.4% (n=17, p<0.05) compared to DMSO control, 
decreased by 112.1 ± 4.5% in SNAP (SNAP + carbenoxolone versus SNAP; n=7, 
p<0.05), and decreased by 170 ± 4.3% (GSNO + carbenoxolone versus GSNO; n=7, 
p<0.05) compared to GSNO treated mitochondria (Figure 3.7). In contrast, IFM did 
not show alterations of K+ influx in response to NO donors or carbenoxolone (n=7; 
p=ns) (Figure 3.8).  
The experimental set up was proven by applying valinomycin, a K+-specific 
ionophore, which transports K+ ions through membranes following their 
electrochemical gradient. Among different treatment groups of mitochondria no 
difference in velocity of mitochondrial K+-influx was detected for the first two seconds 
after application of 5 nm valinomycin conforming equal loading of PBFI dye. The 
measured increase of fluorescence intensity subsequent to valinomycin application 
confirmed integrity of mitochondrial membranes during experimental measurements 
(Figure 3.7C, 3.8C and 3.9C).     
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Figure 3.7: K+ permeability of SSM. Analysis of K+ influx was measured in SSM from the LVs of rat hearts 
treated either with 1 µM carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-
nitrosoglutathione (GSNO) a combination of NO donor and hemichannelblocker (SNAP + carbenoxolone; 
GSNO + carbenoxolone), or dimethyl sulfoxide (DMSO; used as solvent). The increase in the PBFI 
fluorescence ratio (arbitrary units) was measured after an initial KCl pulse of 140 mmol. Oligomycin, 
glibenclamide, and cyclosporine were present during the entire experiment to measure K+ influx 
exclusively via Cx43 hemichannels (A). The rate of PBFI fluorescence ratio (340/380 nm) change from 
mitochondria in different treatments was estimated for the initial 2 seconds after the addition of a KCl pulse 
(B). Valinomycin, a K+ transporter, was added for validation of equal PBFI loading of intact mitochondria 
(C). Data correspond to mean ± SEM of 6–17 replicates per group. * (p<0.05) indicates significant 
differences between marked groups. 
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In addition, K+ influx was inhibited in concentrations of 10 µM carbenoxolone by 
140.5 ± 34.2% compared to DMSO control (n=8, p<0.05) and decreased by 332.1 ± 
21.6% compared to SNAP treated mitochondria (SNAP + carbenoxolone versus 
SNAP; n=8, p<0.05). With 25 µM of carbenoxolone, K+ influx was decreased by 
990.0 ± 151.2% compared to DMSO control (n=7, p<0.05), decreased compared to 
SNAP treated mitochondria by 172.5 ± 36.5% (SNAP + carbenoxolone versus SNAP; 
n=7, p<0.05) and decreased by 167.2 ± 25.5% compared to GSNO treated samples 
(GSNO + carbenoxolone versus GSNO; n=7, p<0.05) (Figure 3.9). Confirming, that 
carbenoxolone had a similar inhibitory effect in a concentration range from 1–25 µM. 
Figure 3.8: K+ permeability of IFM. Analyses were performed with IFM to address the NO mediated 
increase in K+ influx in the absence of Cx43. The increase in the PBFI fluorescence ratio (arbitrary 
units) was measured after an initial KCl pulse of 140 mM. Oligomycin, glibenclamide, and cyclosporine 
were present during the entire experiment to measure K+ influx exclusively via Cx43 hemichannels (A). 
The rate of change of the PBFI fluorescence ratio (340/380 nm) from mitochondria in different 
treatments was estimated for the initial 2 seconds after the addition of a KCl pulse (B). Valinomycin, a 
K+ transporter, was added for validation of equal PBFI loading of intact mitochondria (C). Data 
correspond to mean ± SEM of 5–8 replicates per group. * (p<0.05) indicates significant differences 
between marked groups. 
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SNO mediated K+ influx through Cx43 hemichannels was also measured without 
additional mitochondrial channel blockers. The data showed a NO mediated increase 
of K+ influx, which was weaker with SNAP versus DMSO (138.9 ± 30.7%, n=7, 
p<0.05) compared with SNAP versus DMSO with additional mitochondrial channel 
blockers. GSNO also increased K+ permeability compared to control (119.7 ± 16.0%, 
n=7, p<0.05) as was the case in experiments where the K+ permeability for Cx43 HCs 
was measured in the presence of inhibitors. The NO mediated increase of K+ influx 
was blocked by carbenoxolone (154.6 ± 10.1% for 0.5 mM SNAP with 1 µM 
carbenoxolone and 103.8 ± 25.2% for 1 mM GSNO with 1 µM carbenoxolone; n=7, 
p<0.05)  (Figure 3.10). 
Figure 3.9: Mitochondrial K+ permeability with 10 µM CBX. Analysis of K+ influx was measured in SSM 
treated either with 10 µM carbenoxolone (CBX) (A), or 25 µM carbenoxolone (B), S-nitroso-N-acetyl-
DL-penicillamine (SNAP), S-nitrosoglutathione (GSNO), a combination of NO donor and 
hemichannelblocker (SNAP + carbenoxolone; GSNO + carbenoxolone), or dimethyl sulfoxide (DMSO; 
used as solvent). The increase in the PBFI fluorescence ratio (arbitrary units) was measured after an 
initial KCl pulse of 140 mmol. Oligomycin, glibenclamide, and cyclosporine were present during the 
entire experiment. The rate of PBFI fluorescence ratio (340/380 nm) change from mitochondria was 
estimated for the initial 2 seconds. Data correspond to mean ± SEM of 6–8 replicates per group. * 
(p<0.05) indicates significant differences between marked groups. 
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3.1.4 Mitochondrial sodium uptake 
Permeability for Na+ was measured using sodium binding benzoflur (SBFI). The 
sodium sensitive indicator functions similarly to PBFI. Mitochondrial sodium influx 
was calculated based on an extinction shift and estimated by calculation of a 340 
nm/380 nm ratio. Mitochondrial Na+ was depleted and then measurements were 
performed at 340 nm and 380 nm in a fluorometer with high sensitivity. Velocity of 
mitochondrial Na+ influx was estimated after a sodium chloride pulse of a 
physiological concentration of 10 mM and after an application of 140 mM sodium 
chloride. Additional inhibitors for MPTP, ATP-synthase, and ATP-dependent 
potassium channels were supplemented to strengthen a Cx43 hemichannel 
dependent effect. Measurements performed in isolation buffer under steady state IV 
conditions at 340 nm (Figure 3.11A) and 380 nm (Figure 3.11B) showed no relevant 
mitochondrial sodium influx after treatment either with 1 µM carbenoxolone, 0.5 mM 
SNAP, 1 mM GSNO, a combination of NO donor and carbenoxolone, or 5 µl DMSO. 
Figure 3.10: Mitochondrial K+ permeability with 25 µM CBX. Analysis of K+ influx under physiological 
conditions was measured without adding additional mitochondrial channel blockers to SSM from LVs 
of rat hearts (A). Mitochondria were either treated with carbenoxolone (CBX), S-nitroso-N-acetyl-DL-
penicillamine (SNAP), S-nitrosoglutathione (GSNO), a combination of NO donor and hemichannel 
blocker (SNAP + carbenoxolone; GSNO + carbenoxolone), or dimethyl sulfoxide (DMSO; used as 
solvent). The increase in the PBFI fluorescence ratio of 340/380 nm (arbitrary units) was measured 
for 2 seconds after an initial KCl pulse of 140 mM. The K+ transporter valinomycin was added for 
validation of equal PBFI loading and confirming integrity of mitochondrial membranes (B). Data 
correspond to mean ± SEM of 6–12 replicates per group. * (p<0.05) indicates significant differences 
between marked groups.   
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Experimental set up function was proven by application of gramicidin, which forms a 
channel for sodium in the mitochondrial membrane leading to maximal Na+ influx.  
 
 
Figure 3.11: Mitochondrial sodium (Na+) permeability. Na+ influx was measured in isolated 
subsarcolemmal mitochondria (SSM) from the left ventricles of rat hearts. Mitochondria were treated 
either with carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitrosoglutathione 
(GSNO) a combination of a NO donor and hemichannel blocker (SNAP + carbenoxolone; GSNO + 
carbenoxolone), or dimethyl sulfoxide (DMSO; used as solvent). Measurements were performed in 
isolation buffer supplemented with oligomycin, glibenclamide, and cyclosporine A inhibiting the 
mitochondrial channels, MPTP, ATP-synthase, and ATP-dependent potassium channels to increase 
the effect of Cx43 hemichannel permeability. The intensity of SBFI fluorescence was measured from 
mitochondria in different treatments (here representative shown for DMSO, carbenoxolone, and 
SNAP) at excitations of 340 nm (A) and 380 nm (B) during the addition of 10 mM and 140 mM 
sodium chloride (NaCl) pulses, as well as application 5 nM gramicidin used as control. Data for 
mitochondrial Na+ permeability was not analyzed for the 5 replicates per group, because of the lack 
of Na+ influx.  
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Application of 5 nM gramicidin led to a Na+ influx with a non-differing velocity among 
treatment groups which confirmed sufficient and equal mitochondrial SBFI loading 
(Figure 3.17).       
 
 
 
 
 
The experiments were also performed in succinate buffer under energized conditions 
with rotenone inhibiting complex I favoring complex II respiration. The Na+ influx was 
analyzed for 2 seconds after a 10 mM and a 140 mM sodium chloride pulse (Figure 
3.13). With the 140 mM pulse, mitochondrial Na+ influx was highly increased in 
succinate buffer compared to the experiments performed under steady state IV 
conditions. Between groups only non-significant changes in Na+ fluxes were 
measured (n=6, p=ns). Overall, only low Na+ fluxes were measured compared to the 
measurements of K+ fluxes suggesting that mitochondrial Cx43 HCs have certain ion 
selectivity. 
Figure 3.12: Mitochondrial sodium (Na+) influx using a Na+ transporter. The experimental set up of 
Na+ influx measurements was controlled by application of 5nM Na+ transporter gramicidin after 
application of Na+ pulses (A). The rate of SBFI fluorescence ratio (340/380 nm) change from 
mitochondria in different treatments was estimated for the initial 2 seconds after the addition of 
gramicidin (B). Data correspond to mean ± SEM of 5 replicates per group.  
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The gramicidin induced Na+ influx did not differ between treatment groups of 
mitochondria also in case of experiments performed in succinate buffer favoring 
mitochondrial complex II respiration (Figure 3.14). 
 
Figure 3.13: Mitochondrial sodium (Na+) permeability during complex II respiration. Subsarcolemmal 
mitochondria (SSM) were isolated from the left ventricles of rat hearts and either treated with 
carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitrosoglutathione (GSNO), a 
combination of a NO donor and hemichannel blocker (SNAP + carbenoxolone; GSNO + 
carbenoxolone), or dimethyl sulfoxide (DMSO; used as solvent). Measurements were performed in 
succinate buffer. Specificity of Cx43 hemichannel permeability was increased in the measurements 
by supplementing oligomycin, glibenclamide, and cyclosporine A through inhibiting of mitochondrial 
channels, MPTP, ATP-synthase, and ATP-dependent potassium channels. The rate of SBFI 
fluorescence ratio (340/380 nm) change from mitochondria in different treatments was measured 
during the addition of 10 mM (A) and 140 mM (B) sodium chloride (NaCl) pulses. The fluorescence 
increase was analyzed for the first two seconds following to the pulse. Data correspond to mean ± 
SEM of 5 replicates per group.  
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3.1.5 ROS production  
Endothelial NOS docks to the mitochondrial outer membrane producing local NO 
[94], therefore, whether or not NO can regulate ROS via SNO of mitochondrial Cx43 
is of interest. Mitochondrial ROS production was measured with 25 µM 
carbenoxolone, 0.5 mM SNAP, 1 mM GSNO, a combination of NO donor and 
carbenoxolone, or 20 µl dH20. ROS production was measured with glutamate/malate 
as a substrate for complex 1 respiration with ADP stimulation. The application of NO 
donor SNAP enhanced ROS formation by 22.9 ± 1.8% (n=9, p<0.05) compared to 
control. Application of NO donor GNSO led to an increase of ROS production by 40.6 
± 7.1% (n=9, p<0.05) compared to control. The NO mediated increases were 
abolished by application of 25 µM carbenoxolone (Figure 3.15A). Antimycin A 
blockades the electron transfer form coenzyme Q to cytochrome C at respiration 
chain complex III, thus leading to circulation of electrons between complex I and 
complex III causing maximal ROS formation. Therefore antimycin A was used as a 
Figure 3.14: Control of mitochondrial SBFI loading. Equal SBFI 
loading of different subsarcolemmal mitochondrial (SSM) 
treatment groups (details, see text) was controlled by measuring 
sodium influx after application of 5 nM sodium transporter 
gramicidin. The rate of SBFI fluorescence ratio (340/380 nm) 
change from mitochondria in different treatments was estimated 
for the initial 2 seconds after the addition of gramicidin. Data 
correspond to mean ± SEM of 5 replicates per group. 
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control and was applied at the end of baseline ROS formation measurements. After 
antimycin A application ROS formation was increased approximately by 6–12 times 
compared to baseline ROS generation. After antimycin A application, in samples 
receiving GSNO, ROS formation was significantly reduced by 44.2 ± 7.7% (n=9, 
p<0.05) compared to other treatment groups (Figure 3.15B).     
 
 
 
 
 
 
 
 
IFM were used to validate Cx43-dependent increases of ROS formation due to NO. 
Application of NO donors in IFM decreased ROS production. SNAP decreased ROS 
formation by 14.4 ± 4% (n=9, p<0.05) compared to control and GSNO by 13.8 ± 4%, 
n=9, p<0.05) compared to control. Carbenoxolone had no significant inhibitory effect 
on ROS production with ADP stimulated complex 1 respiration (n=9, p=ns) (Figure 
3.16). 
Figure 3.15: Nitric oxide influence on ROS formation (H2O2 production) of subsarcolemmal 
mitochondria (SSM). Measurements of ROS generation (H2O2 production) were performed on freshly 
isolated SSM treated with carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-
nitrosoglutathione (GSNO), a combination of a NO donor and hemichannel blocker (SNAP + 
carbenoxolone; GSNO + carbenoxolone), or dH2O. Mitochondrial H2O2 production was measured 
during ADP stimulated complex 1 respiration for 4 minutes and the increase of H2O2 was expressed in 
nM/min/mg protein by comparing the data to a standard curve (A). Subsequently, antimycin A was 
added for measuring maximal mitochondrial ROS production serving as a positive control (B). Data 
correspond to mean ± SEM of 9 replicates per group. * (p<0.05) indicates significant differences 
between marked groups or significant difference between marked and non-marked groups.    
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The impact on mitochondrial ROS generation of 1 µM GSNO or 48 nM GSNO was 
investigated. Again, mitochondrial ROS production was increased by 20 ± 3.7% 
(n=16, p<0.05) in samples treated with 1 µM GSNO compared to control and 50 nM 
GSNO increased mitochondrial ROS formation by 14.3 ± 2.8 (n= 13, p<0.05) 
compared to control.  
The Cx43 mimetic peptide Gap26 binds to the first extracellular loop of Cx43, thereby 
inhibiting Cx43 HC opening [288], whereas carbenoxolone inhibits formation of Cx43-
formed channels [70]. Mitochondria treated with Gap26 showed no alterations in 
baseline ROS formation, but Gap26 abolished the NO induced increase in ROS 
formation. In Gap26 treated SSM the ROS formation was decreased about 14.3 ± 2.8 
(n= 13, p<0.05) compared to GSNO treated mitochondria (Figure 3.17).  
Figure 3.16: Nitric oxide influence on ROS formation (H2O2 production) of interfibrillar mitochondria 
(IFM). Measurements of ROS generation was performed on freshly isolated IFM treated with 
carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitrosoglutathione (GSNO), a 
combination of a NO donor and hemichannel blocker (SNAP + carbenoxolone; GSNO + 
carbenoxolone), or dH2O. Mitochondrial H2O2 production was measured during ADP stimulated 
complex 1 respiration for 4 minutes and the increase of H2O2 was expressed in nM/min/mg protein 
by comparing the data to a standard curve (A). Subsequent antimycin A was added for measuring 
maximal mitochondrial ROS production serving as a positive control (B). Data correspond to mean ± 
SEM of 9 replicates per group. * (p<0.05) indicates significant differences between marked and 
unmarked groups.    
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Additionally ROS measurements were performed with the respiratory complex I 
inhibitor rotenone. Inhibition of complex I lead to increased formation of the primary 
electron donor ubisemiquinone. The present data show increased mitochondrial ROS 
formation after rotenone application. However, mitochondrial ROS formation did not 
differ in the presence of rotenone in different mitochondrial treatment groups (n=6, 
p=ns) and the NO mediated increase of ROS formation was abolished (Figure 3.18).  
 
 
Figure 3.17: Low concentration nitric oxide influence on ROS formation (H2O2 production) of 
subsarcolemmal mitochondria (SSM). Measurements of ROS generation were also performed on 
freshly isolated SSM with low concentrations (1 µM and 48 nM) of S-nitrosoglutathione (GSNO) (A), 
and additional experiments were performed with Cx43 mimetic peptide GAP26, an inhibitor of Cx43 
hemichannels or carbenoxolone (CBX). Mitochondrial H2O2 production was measured during ADP 
stimulated complex 1 respiration and was expressed in nM/min/mg protein. Data correspond to mean 
± SEM of 13–20 replicates per group. * (p<0.05) indicates significant differences between marked 
groups or significant difference between marked and unmarked groups.    
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The respiratory chain uncoupling agent FCCP, which inhibits mitochondrial 
membrane potential, was used as a negative control. Application of FCCP 
significantly decreased ROS formation, and ROS generation did not differ between 
different treatment groups (Figure 3.19).  
 
 
 
Figure 3.19: Nitric oxide influence on ROS formation (H2O2 generation) of subsarcolemmal 
mitochondria (SSM) with respiration chain uncoupling. Measurements of ROS generation were also 
performed on SSM in the presence of respiration chain uncoupler FCCP (A and B). Mitochondrial 
H2O2 production was measured during ADP stimulated complex 1 respiration and was expressed in 
nM/min/mg protein. Data correspond to mean ± SEM of 6–10 replicates per group.  
 
Figure 3.18: Nitric oxide influence on ROS formation (H2O2 production) of subsarcolemmal 
mitochondria (SSM) with inhibition of respiration chain complex I. Measurements of ROS generation 
were performed on SSM in the presence of respiration chain complex I inhibitor rotenone (A and B). 
Mitochondrial H2O2 production was measured during ADP stimulated complex 1 respiration and was 
expressed in nM/min/mg protein. Data correspond to mean ± SEM of 6–9 replicates per group.  
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3.1.6 Quantification of SNO modified mtCx43 after NO donor 
application 
SNO quantification analyses were performed on mitochondria isolated by density 
gradient ultracentrifugation. Purity of mitochondrial preparation was determined by 
the absence of immunoreactivity for antibodies directed against markers of the 
plasma membrane (Na+/K+-ATPase), sarcoplasmic reticulum (SERCA2 ATPase), 
nucleus (HDAC), cytosol (GAPDH) and enrichment of mitochondrial proteins (TOM20 
and MnSOD) (Figure 3.20A). A modified biotin switch method was utilized for labeling 
SNO modified proteins with biotin (BIAM) (Figure 3.20B). Following precipitation and 
Western blot analysis, intensity of the 43 kDa bands representing SNO-modified 
mtCx43 was significantly increased in mitochondria incubated with NO donors. 
Samples treated with GSNO, SNAP, or a combination of a NO donor and Cx43 HC 
blocker carbenoxolone showed an increase in SNO modifications of mtCx43 in 
average by 109.2 ± 21.5% (n=7, p<0.05) compared to mitochondria not treated with a 
NO donor (Figure 3.20C,D and E). The reason for applying the HC blocker 
carbenoxolone was to exclude it’s NO interfering properties. Additionally as a control, 
DTT was applied to NO donor treated and biotin labeled samples to break disulfide 
bounds confirming specificity of the biotin switch method. In samples treated with 100 
mM DTT the Cx43 band was not present or was highly reduced (Figure 3.20D). In 
mitochondria treated with 10 mM DTT and the NO donor SNAP the amount of SNO 
modified mtCx43 was significantly reduced by 59.7 ± 7.6% compared to NO treated 
samples and reduced by 15.8 ± 7.8% (n=7, p<0.05) compared to untreated samples 
(Figures 3.20C and 3.20E).                
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Figure 3.20: Quantification of SNO modified mtCx43 for nitric oxide treated mitochondria. SNO 
quantification was performed on mitochondria treated either with carbenoxolone (CBX), S-nitroso-N-
acetyl-DL-penicillamine (SNAP), S-nitrosoglutathione (GSNO), a combination of NO donor and 
hemichannel blocker (SNAP + carbenoxolone; GSNO + carbenoxolone), or dimethyl sulfoxide 
(DMSO; used as solvent). Purity of subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria 
(IFM) preparations was determined by the absence of immunoreactivity for antibodies directed against 
cellular markers and enrichment of mitochondrial proteins (A). Using a modified biotin switch method, 
SNO modified cysteine residues of mitochondrial proteins were labeled with biotin (B). Subsequent to 
precipitation of biotin labeled SNO modified proteins, Western blot analyses were performed for 
mtCx43 (C+D). Biotin labeled mitochondria were treated with 10 mM DTT (C) or 100 mM DTT (D) for 
validation of the specificity of the biotin switch method. Band signal intensity of purified SNO modified 
mtCx43 was normalized to a loading control taken from the starting mitochondrial lysate, representing 
the total amount of loaded mtCx43. * (p<0.05) indicates significant difference to unmarked groups. 
Results are expressed as mean ± SEM of 7 replicates per group (E). 
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3.1.7 Identification of mtCx43 phosphorylation induced by NO  
Changes in mtCx43 phosphorylation status, which can also affect HC open 
probability, were analyzed subsequent to NO donor exposure and addition of HC 
blocker carbenoxolone. SSM were incubated either with 1 µM carbenoxolone, 0.5 
mM of NO donor SNAP, 1 mM of NO donor GSNO, a combination of a NO donor and 
carbenoxolone, or 5 µl DMSO used as a vehicle. The Western blot analysis showed 
only changes in mtCx43 phosphorylation for serine residue 365 (pS365) in response 
to administration of NO donor SNAP. MtCx43’s pS365 was tendentially increased by 
71.4 ± 33.4% (n=4, p=ns) in SNAP treated samples compared to the control group 
(Figure 3.21B). Phosporylation of the Cx43 epitopes S368 and S373 were not altered 
among different treatment groups (n=4, p=ns) (Figure 3.21B and 3.21C). 
 
 
Results  55 
 
 
   
 
 
 
 
 
 
 
Figure 3.21: Western blot analyses of Cx43 serine phosphorylation. Subsarcolemmal mitochondria 
(SSM) treated either with carbenoxolone (CBX), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-
nitrosoglutathione (GSNO), a combination of a NO donor and the hemichannel blocker (SNAP + 
carbenoxolone; GSNO + carbenoxolone), or dimethyl sulfoxide (DMSO; used as solvent) were 
isolated by Percoll gradient ultracentrifugation. Purity of preparations was determined by the absence 
of immunoreactivity for antibodies directed against markers of the plasma membrane (Na+/K+-ATPase) 
and increase of mitochondrial protein (MnSOD). Band intensity of Cx43 phosphorylated serine 
residues S365 (pS365), S368 (pS368), and S373 (pS373) were normalized to total mtCx43 (A). 
Relative amount of serine phosphorylation was quantified and expressed as a ratio normalized to total 
mtCx43 ratio (B-D). * (p<0.05) indicates a significant difference in comparison with unmarked groups. 
Results are expressed as mean ± SEM of 4–5 replicates per group. 
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3.2 The link between SNO of mtCx43 and the signal 
transduction cascade of preconditioning 
In order to identify a link between SNO of mtCx43 and the signal transduction 
cascade of cardioprotection, preconditioned mitochondria were analyzed for the rate 
of dye permeability and the amount of posttranslational SNO modification of mtCx43. 
Additionally, proteomic approaches were used to identify SNO modified cysteine 
residues.    
 
3.2.1 Analysis of mitochondrial dye permeability after IPC   
The dye permeability of mitochondria receiving IPC was analyzed to support a 
possible link between SNO of mtCx43 and the signal transduction cascade of 
cardioprotection. Therefore, SSM were isolated from the LV of rat hearts, which 
received IPC or were control perfused in Langendorff experiments. Following 
incubation with 50 µM of the HC permeable dye LY or 25 µg/ml of the HC 
impermeable dye RITC-dextran, mitochondria receiving IPC showed a 13 ± 4.6% 
higher LY fluorescence intensity (n=4, p<0.05) compared to control mitochondria. 
Additional experiments were performed with IPC and control mitochondria which 
were exposed for 10 minutes to daylight. These experiments were done to confirm a 
SNO dependent effect of increased mitochondrial dye permeability due to IPC, since 
SNO protein modifications are light sensitive. After exposure to daylight, 
preconditioned and control mitochondria did not show a difference in LY uptake (n=4, 
p=ns). Fluorescence intensity of RITC-dextran did not differ among treatment groups 
(n=4, p=ns) (Figure 3.22). 
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3.2.2 Quantification of SNO modified mtCx43 after IPC 
In order to investigate if SNO of mtCx43 is increased with IPC, rat hearts were once 
again assigned to a Langendorff perfusion protocol. One group of hearts was 
preconditioned, while the other group was constantly normo-perfused (control). 
Subsequent to isolation of mitochondria by ultra-gradient centrifugation, the purity of 
the mitochondrial preparation was analyzed by Western blot analysis for the absence 
of immunoreactivity of antibodies for cellular marker proteins and enrichment of 
mitochondrial proteins (Figure 3.23A). Western blot analysis was also performed to 
quantify the amount of Cx43 per mitochondrion and showed an increase of 64.8% ± 
17% (n=8, p<0.05) (Figures 3.23B and C). This confirms previously published data 
that demonstrate that the mitochondrial amount of Cx43 is increased after IPC. 
Figure 3.22: Mitochondrial Lucifer yellow (LY) dye uptake of mitochondria isolated from 
preconditioned hearts. Rat hearts were Langendorff perfused, one group received IPC and the other 
group was control perfused. Subsequent dye uptake of the hemichannel permeable dye LY (left 
panel) and the hemichannel impermeable dye RITC-dextran (right panel) of isolated mitochondria 
was measured. Dye uptake was quantified by measuring fluorescence intensity expressed as 
arbitrary units. As a control, mitochondria were exposed to daylight, which breaks down light 
sensitive SNO modifications before incubation with dyes. Data are shown as mean ± SEM of 4 
replicates per group. * (p<0.05) indicates significant differences between groups.   
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A modified biotin switch method for labeling SNO modified cysteine residues was 
used and the amount of SNO modified mtCx43 was quantified for each group. The 
quantification of SNO modified mtCx43 showed that the relative amount of SNO 
modified mtCx43 was significantly increased by 41.6 ± 1.7% (n=17, p<0.05) in 
preconditioned rat hearts compared to control perfused hearts (Figures 3.24A and B). 
Additionally, perfusion of rat hearts was performed in daylight and here the increase 
in light sensitive SNO modification was lost (n=6, p=ns). Furthermore, adding DTT, 
which breaks down disulfide bounds, after SNO labeling led to a decrease of 
precipitated protein and the significant difference between the groups was abolished 
(n=5, p=ns) (Figures 3.24C, D, and E). 
 
 
Figure 3.23: Quantification of mtCx43 after ischemic preconditioning (IPC). Rat hearts were 
assigned to a Langendorff perfusion model. One group was preconditioned while the other was 
constantly normo-perfused (control). SNO quantification of mtCx43 was performed on mitochondria 
isolated by Percoll gradient ultracentrifugation. Western blot analysis showed that mtCx43 is 
increased following IPC when normalized to mitochondrial protein MnSOD (B and C). Results are 
expressed as mean ± SEM of 8 replicates of IPC and control perfused hearts. * (p<0.05) indicates 
significant difference between groups. 
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Figure 3.24: SNO quantification of mtCx43 after ischemic preconditioning (IPC). Rat hearts were 
assigned to a Langendorff perfusion model, either receiving IPC or constantly normoperfusion 
(control). Using a modified biotin switch method, biotin labeled SNO modified proteins were 
precipitated; Western blot analyses were performed for mtCx43 (A, C, and D). Interfibrillar 
mitochondria (IFM) were used as a negative control. The right ventricle of rat hearts was used as a 
positive control. Band signal intensity of purified SNO modified mtCx43 was normalized to a loading 
control taken from the starting mitochondrial lysate representing the total amount of loaded mtCx43 
(B). In addition, as negative controls, Langendorff experiments were repeated by daylight to remove 
light sensitive SNO modification (C). Isolated mitochondria were treated with DTT to remove the 
SNO/biotin label showing specificity of the biotin switch method (D). * (p<0.05) indicates significant 
differences between groups. Results are expressed as mean ± SEM of 14 replicates of IPC and 
control perfused hearts (B). Five to six replicates per group of negative controls were performed (E).  
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3.2.3 Quantification of SNO modified mtCx43 after rIPC 
SNO of mtCx43 was quantified subsequent to rIPC of mouse hearts. One group of 
mice received rIPC by hindlimb ischemia and reperfusion, whereas the control group 
received the same treatments except the peripheral ischemia/reperfusion episodes. 
SNO of mtCx43 was increased by 65.7 ± 16.9% (n=5, p<0.05) in mice receiving rIPC 
compared to control treated mice. Additionally, mice were pharmacological 
preconditioned by injection of 48 nM sodium nitrite into the cavity of left ventricle, 
which increased SNO modified mtCx43 by 59.3 ± 18.2% (n=6, p<0.05) compared to 
control mice receiving sodium chloride injections (Figure 3.25). 
 
      
 
 
 
 
 
 
 
 
In addition, the relative amount of precipitated SNO modified mtCx43 was quantified 
by normalizing SNO of mtCx43 to total mtCx43 on a Western blot. The results 
showed that only approximately 0.46 ± 0.01% of the total mtCx43 was SNO modified 
Figure 3.25: SNO quantification of mtCx43 after remote ischemic preconditioning (rIPC). Mice 
received rIPC by hindlimb ischemia and reperfusion or were pharmacological preconditioned by 
injection of 48 nM sodium nitrite into the left ventricle. Subsequently subsarcolemmal mitochondria 
(SSM) were isolated from the left ventricle of these treated mice hearts. Purity of the mitochondrial 
preparation was confirmed by the absence of immunoreactivity for sarcolemma marker Na+/K+-
ATPase and enrichment of mitochondrial protein MnSOD. Biotin labeled SNO modified proteins were 
precipitated and Western blot analyses were performed for mtCx43 (A). Interfibrillar mitochondria 
(IFM) were used as a negative control. The right ventricle were used as positive a control. Band 
signal intensity of purified SNO modified mtCx43 was normalized to a loading control taken from the 
starting mitochondrial lysate representing the total amount of loaded mtCx43 (B). * (p<0.05) indicates 
significant difference between marked groups. Results are expressed as mean ± SEM of 5–6 
replicates per group.  
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in control treated left ventricle of mice hearts (Figure 3.26). The content of SNO of 
mtCx43 was increased by 60% by rIPC.  
 
 
 
 
 
3.2.4 Identification of SNO modified cysteine residues of mtCx43 
Using liquid chromatography tandem mass spectrometry, SNO modified cysteine 
residues of mtCx43 were identified following IPC and constantly normo-perfused 
(control) rat hearts. In IPC treated rat hearts 7 distinct peptides were identified 
covering 33.5% of Cx43’s amino acid (aa) sequence. Analysis of mtCx43 from control 
perfused rat hearts identified 9 distinct peptides covering 35.3% of the aa sequence 
(Table 3.1).  
Figure 3.26: Quantification of the relative amount of SNO modified mtCx43. Purity of isolated 
mitochondria from the left ventricle of mice hearts was confirmed by the absence of immunoreactivity 
for sarcolemma marker Na+/K+-ATPase and enrichment of mitochondrial protein MnSOD. Biotin labeled 
SNO modified proteins were precipitated and Western blot analyses were performed for mtCx43. The 
right ventricle of mice hearts were used as positive a control. Results are expressed as mean ± SEM of 
2 replicates per group.  
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In IPC samples two SNO modified cysteine residues (Cys54
 
and Cys271) labeled 
with a carbamidomethyl and five unmodified cysteine (Cys61, Cys187, Cys192, 
Cys198, and Cys298) with NEM labels were identified. In constantly (control) 
normoperfused rat hearts four SNO modified cysteine residues of mtCx43 and two 
unmodified cysteine thiols were detected (Figure 3.27). Cx43 peptides and SNO of 
mtCx43 were only detectable in low abundance, therefore quantification of SNO 
modified cysteines by analyzing the ratio of peptide containing carbamidomethyl 
Treatment  Peptide sequence Range SNO Cys  Unmodified Cys No.  
IPC CNTQQPGCENVCYDKSFPISHVR   54 - 76 
1: Carbamidomethyl 
(Cys54) 8: NEM (Cys61) 1 
 
VAQTDGVNVEM
HLK 115 - 128   1 
 FKYGIEEHGKVK  135 - 146   2 
 
SVFEVAFLLIQWY
IYGFSLSAVYTCK   
 
163 - 188 
 
 25: NEM (Cys187) 1 
 
RDPCPHQVDCFL
SRPTEK   189 - 206  
4: NEM (Cys192), 
10: NEM (Cys198) 2 
 
YAYFNGCSSPTA
PLSPMSPPGYK 
  
265 - 289 7: (Carbamidomethyl) (Cys271) 
 
 
1 
 LVTGDRNNSSCR 290 - 301  11: NEM (Cys298)  1 
Control 
CNTQQPGCENV
CYDKSFPISHVR   
 
54 - 76 
 
1: Carbamidomethyl 
(Cys54) 12: NEM (Cys65) 2 
 
VAQTDGVNVEM
HLK  
115 - 128 
 
  1 
 FKYGIEEHGKVK  135 - 146   1 
 VKMRGGLLR  145 - 153   1 
 
RDPCPHQVDCFL
SRPTEK   
189 - 206 
 
4: Carbamidomethyl 
(Cys192), 
10:Carbamidomethyl 
(Cys198) 
4: NEM (Cy192), 
10: NEM (Cys198) 2 
 
SDPYHATTGPLS
PSK  
 
244 - 258 
 
  1 
 
YAYFNGCSSPTA
PLSPMSPPGYK 
  
265 - 289 7: (Carbamidomethyl) (Cys271) 
 
 
1 
 
LVTGDRNNSSCR 
 
290 - 301  11: NEM (Cys298)  
 
1 
 ASSRASSRPR  367 - 376   2 
Table 3.1: Peptides identified by liquid chromatography tandem mass spectrometry. SNO modified cysteine residues 
of mtCx43 were labeled with a carbamidomethyl and unmodified cysteine with NEM. Also displayed is the number of 
peptides identified in 4 trials.    
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labeled cysteines to total detected cysteine residues was not possible with proteomic 
approaches.        
 
 
 
 
Figure 3.27: Schematic display of mtCx43 showing cysteine modifications identified by proteomic 
approaches. Mitochondria from ischemic preconditioned (IPC) and constantly (control) normo-perfused 
rat hearts were analyzed by proteomic approaches for identifying SNO modified cysteine residues of 
mtCx43. The cysteine residues (C) of mtCx43 are marked in red. Identified cysteine residues by liquid 
chromatography tandem mass spectrometry are circled in red showing detected unmodified cysteine 
thiols. Circled in green are SNO modified cysteine residues.      
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4. Discussion  
 
4.1 S-nitrosation of mtCx43 influences mitochondrial 
function  
Mitochondrial permeability for the LY dye and K+ are increased following to the 
application of the NO donors SNAP and GSNO in SSM, but not in IFM. Interestingly, 
the change in mitochondrial permeability for Na+ was minor and not influenced by the 
NO donors. The NO mediated increases in mitochondrial permeability were abolished 
by the Cx43 hemichannel blocker, carbenoxolone. ROS formation of SSM was also 
increased in the presence of NO donors. However, the ROS increasing effect of the 
NO donors was abolished by carbenoxolone or the Cx43 mimetic peptide Gap26, 
which blocks of HC opening. In contrast to SSM, in IFM ROS formation was 
decreased in response to NO donors. Furthermore, SNO of mtCx43 was increased in 
response to the application of NO. These new findings indicate that SNO of mtCx43 
contributes to the regulation of mitochondrial permeability, especially for K+ fluxes 
and ROS formation, which might be linked to the modified mitochondrial K+ influx 
[205]. 
 
4.1.1 Reduction of mitochondrial permeability by carbenoxolone 
confirms the existence of mtCx43 hemichannels  
Carbenoxolone, a glycyrrhetinic acid derivative, is a compound known to block gap 
junctions function by disruption of connexons [96, 293]. Glycyrrhetinic acid derivative 
intercalate in membranes inducing a conformational change and disrupts  connexin 
hemichannels by direct interaction [67]. Cross-linking studies on mtCx43 confirm the 
presence of hexamer-like structures in the inner mitochondrial membrane. The 
existence of mtCx43 HCs is further supported by reduced mitochondrial LY uptake in 
response to HC blockers carbenoxolone and heptanol. The present results indicate 
that 1 µM carbenoxolone is sufficient to significantly reduce mitochondrial LY uptake 
confirming successful disruption and thereby inhibition of mtCx43-formed HCs [167]. 
In experiments with human fibroblasts 3 µM carbenoxolone reduced inter junctional 
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communication by 80% and 6 µM completely blocked intercellular transfer of 
phenylalanine [306]. 
Carbenoxolone at a concentration of 100 µM led to a rapid decrease of phenylalanine 
incorporation representing overall protein synthesis, suggesting increased cellular 
toxicity of the drug at high concentrations [68]. Exposure of 50 µM carbenoxolone led 
to loss of mitochondrial membrane potential in astrocytes and neurons [283]. Studies 
on rat liver mitochondria showed that carbenoxolone induced mitochondrial swelling 
and the collapse of mitochondrial membrane potential via ROS formation and MPTP 
opening. In the present study, investigating the impact of carbenoxolone on SSM 
isolated from rat left ventricles showed a loss of mitochondrial membrane potential 
and mitochondrial integrity in response to 35 µM carbenoxolone. The reason for the 
greater sensitivity of mitochondria to carbenoxolone in the present study could be due 
to differences in tissue type or the mitochondrial subpopulation analyzed. However, 
carbenoxolone concentrations up to 25 µM had no impact on mitochondrial vitality, 
but significantly reduced LY uptake and velocity of K+ influx in SSM, but not in IFM 
lacking Cx43. Therefore, previous findings of reduced mitochondrial permeability 
caused by connexin HC blockers were confirmed in the present study. Importantly, 
the Western blot analysis of the present study showed no decrease of SNO of 
mtCx43 by HC blocker carbenoxolone. Accordingly, carbenoxolone blocks the ion 
fluxes and their downstream effects mediated by mtCx43 HCs, but not SNO of 
mtCx43 per se [66, 68].              
 
4.1.2 NO increases mitochondrial permeability 
Endogenously, NO can be produced in specific cellular regions via local NOS 
activation [132, 217]. In cardiomyocytes, specific NOS isoforms located in distinct 
cellular compartments produce NO in a coordinated manner, thereby allowing the 
interaction only with co-localized effectors [107, 304]. NOS isoforms have different 
expression patterns among species. The existence of mitochondrial NOS isoforms 
was proven by immunohistochemistry in rat liver, brain, kidney, skeletal muscle, and 
heart [13, 14] and by biochemical analysis in the myocardium [88, 125, 300]. In 
porcine and rat heart mitochondria the inducible NOS isoform was detected [88, 92], 
whereas in mice heart mitochondria neuronal NOS is expressed [140]. Furthermore a 
study showed that caveolae endothelial NOS localizes with mitochondria and docks 
66  Discussion 
to the mitochondrial outer membrane in the human umbilical vein, human endothelial 
cells, and embryonic kidney cells [94]. However, there are conflicting results 
regarding the existence of specific mitochondrial NOS isoforms [37, 92, 156, 282]. 
There is also evidence of NO generation by non-enzymatic release from nitrite 
independent of NOS isoforms [62], which is suggested to be associated with 
cardioprotection [252, 253]. 
In the present study, the NO mediated increase in mitochondrial permeability was 
measured in SSM, but not in IFM which lack Cx43. The NO mediated increase in 
mitochondrial permeability was abolished by the connexin HC blocker carbenoxolone. 
Changes in the phosphorylation status or in the redox state of connexin regulate the 
open probability of GJs or HCs at the cellular sarcolemma [226, 235]. Studies 
investigating cellular communication within the vessel wall of the mouse artery 
showed an increased open probability of Cx43-formed GJs through SNO of cysteine 
271, whereas denitrosation by compartmentalized S-nitrosoglutathione reductase 
decreased GJ permeability [261]. Investigations on astrocytes by Retamal et al. 
proposed increased GJ permeability with a NO donor application, whereas reducing 
agents inhibited GJ permeability [224]. In this study, the existence of a similar 
mechanism for mitochondrial connexin HCs is proposed.   
Cx43 HCs located at the sarcolemma are predominantly closed during resting 
conditions [216]. The results of the present study showed that SSM and IFM had a 
similar level of LY dye uptake at baseline. This finding indicates that baseline 
mitochondrial permeability for LY is provided also through other mitochondrial 
channels and indicates a low open probability mtCx43 HC. A predominant closed 
confirmation of mtCx43 HC is supported by the fact that, only less than 1% of mtCx43 
is SNO modified under baseline conditions. Nevertheless, HC blocker carbenoxolone 
as well as genetic replacement of Cx43 with Cx32 in mitochondria reduced 
mitochondrial LY dye permeability. This suggests that at least some mtCx43 HCs are 
open in SSM under baseline conditions.  
In addition to the NO-induced increase in Cx43 HC open probability 
dephosphorylation of Ser368 is also able to induce HC opening at the plasma 
membrane. This leads to release of  metabolites, second messengers, and Ca2+ 
which causes cellular damage and induces apoptosis of neighboring cells [60, 113, 
136, 161, 165, 283].  
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Several protein kinases located in the mitochondria including PKC [160, 164, 208], 
protein kinase A [87, 151, 168], and the serine/threonine kinase Akt [22] can 
phosphorylate mtCx43 HC thereby influencing HC stability and open probability. Thus 
it could be possible that mtCx43 HC open probability is altered by SNO mediated 
modification of mitochondrial protein kinase activities. The performed Western blot 
analysis quantifying serine phosphorylation of mtCx43 showed a tendencially 
increase in phosphorylation of serine residue 365 in response to the NO donor 
SNAP. Other tested serine residues or samples treated with the NO donor GSNO 
displayed no alterations in Cx43 phosphorylation. The serine residue 365 of Cx43 
has been viewed as gate keeper in that the epitope must be dephosphorylated in 
order to allow phosphorylation of the serine residue 368 of Cx43, which in turn is 
important for the buildup of HC in the sarcolemma [258].   
 
4.1.3 Ion specificity of NO mediated increased mitochondrial 
permeability  
Previous studies have shown that the HC blocker 18α-glycyrrhetic acid reduced 
mitochondrial K+ influx. In experiments using Cx43KI32 mice, in which Cx43 is absent 
and replaced by Cx32, a reduction in mitochondrial K+ and LY permeability was 
demonstrated [184]. Cx32 has a highly reduced conductivity for K+ [108] and is 
permeable to soluble in a charge dependent manner [97].  
The velocity of mitochondrial K+ influx was increased by NO donors and reduced by 
carbenoxolone. Thus the NO mediated increase in mitochondrial dye permeability 
was confirmed by measurements of K+ influx. The concentration of the K+ pulses (140 
mM) corresponds to the intracellular K+ concentration. The electrochemical gradient 
drives K+ ions into the mitochondrial matrix. Additional mitochondrial potassium 
channels were inhibited during these measurements: MPTP opening was blocked by 
cyclosporine A [110], the proton channel of the ATP-synthase was inhibited by 
oligomycin, and glibenclamide was used to block the opening of ATP-dependent 
potassium (mitoKATP) channels [246, 267], the latter being important for 
cardioprotection by IPC [115, 200]. In the presence of these inhibitors with the 
addition of carbenoxolone a mitochondrial K+ influx was still detectable. It is possible, 
that channels other than mitoKATP channels could contribute to mitochondrial K+ 
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fluxes, among them calcium-dependent potassium channels, mitochondrial Kv1.3 
potassium channels, and the two-pore potassium channels TASK-3 [268]. The fact 
that carbenoxolone significantly reduced mitochondrial K+ influx in the presence of 
many K+ channel inhibitors supports the existence of a mtCx43 HC. Blockade of any 
of the relevant K+ channels might significantly reduce total mitochondrial matric K+ 
levels and thereby inter with ROS formation and the induction of cardioprotection 
(threshold phenomenon). Relevance of the NO mediated increase of mitochondrial K+ 
influx in a physiological context was supported by repeating the experiments without 
additional K+ channel inhibitors, which showed slightly reduced but still significant 
Cx43-dependent increases in the mitochondrial K+ influx.  
It is of interest to note, that mtCx43 HC provide certain ion selectivity. The measured 
Na+ influx was minor and neither the NO donors nor carbenoxolone did alter Na+ 
fluxes significantly. It is proposed that GJs are rather non-ion specific channels and 
Cx43 HCs are characterized as size selective pores with negligible charge-dependent 
selectivity [141]. A number of studies have proposed that Cx43 GJ have certain ion 
selectivity with a preference for K+ over Na+ [287]. This fact could explain the weak 
Na+ fluxes which were measured in the present study. In cardiac mitochondria, the 
Na+ import is mainly achieved by the Na+/Ca2+ exchanger mediating Na+ influx in 
exchange for Ca2+ efflux [146] and Na+ is exported via a mitochondrial Na+/H+ 
exchange system [138]. Metabolic inhibition increases the concentration of Na+ in the 
mitochondrial matrix, whereas in energized mitochondria the concentration of Na+ is 
lower in the matrix compared to the cytosol [76, 138]. Therefore in the present study, 
mitochondria performing on state 4 respiration showed a lack of Na+ influx, whereas a 
weak Na+ flux was detectable in mitochondria during complex II respiration. It has to 
be mentioned further, that a detectable Na+ influx was only measured in response to 
a 140 mM sodium chloride pulse. The physiological concentration of intracellular Na+ 
in cardiomyocyte ranges approximately 5–10 mM [131]. In response to 10 mM 
sodium chloride pulses no significant Na+ influx was detectable even in respiring 
mitochondria. If a mitochondrial Na+ influx was measured it was decreased rather 
than increased in the presence of a NO donor. Since NO inhibits highly selective 
sodium channels in H144 cells at the cellular surface [5] one alternative explanation 
for the observed lack of mitochondrial Na+ influx following NO donors could be a NO 
induced decrease of mitochondrial Na+ permeability via inactivation of mitochondrial 
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sodium channels compensating for a possible increase in Na+ influx through 
increased mtCx43 HC open probability.   
Taken together, it can be assumed that NO induced mtCx43 HC opening mainly 
induces mitochondrial K+ influx.  
 
4.1.4 NO mediated increase in ROS formation in SSM via Cx43 
Low amounts of ROS species function as signaling molecules in endogenous 
cardioprotection [205]. Indeed, cardioprotection induced by diazoxide leads to ROS 
formation which is dependent on mtCx43 [115]. Furthermore there is evidence that 
NO triggers preconditioning [30, 269], and that the cardioprotection achieved by the 
exogenous NO donor SNAP could be abolished by ROS scavengers as well as 
potassium channel blockers [297]. In the present study mitochondrial ROS formation 
was increased in response to NO donors in SSM. The NO triggered increase in 
mitochondrial ROS formation was abolished by uncoupling of Cx43 HCs with 
carbenoxolone indicating that mtCx43 is essential for NO triggered ROS formation. 
Furthermore NO induced ROS formation was blocked by the Cx43 mimetic peptide 
Gap26. Cx43 mimetic peptides have identical sequences to domains of the Cx43 
protein. Gap26 binds the first extracellular loop of Cx43 which inhibits GJ formation 
[84, 292]. More recently studies showed that Gap26 inhibits voltage induced Ca2+ 
currents in ventricular cardiomyocyte indicating an inhibition of Cx43 HC opening 
[288]. Thus the current data indicates that Cx43 HC opening is a necessary 
mechanism for NO triggered mitochondrial ROS formation. ROS triggering 
cardioprotection must be viewed separately from ROS contributing to irreversible 
injury following sustained episodes of ischemia/reperfusion. Indeed, Chouchani et al. 
proposed that NO donor induced SNO of mitochondrial complex 1 provided 
cardioprotection via reduced ROS formation following sustained ischemia and 
reperfusion [54]. The present study adds one more facet in that, the modification of 
ROS formation by NO depends on the subpopulation of mitochondria analyzed. 
Energized IFM in contrary to SSM showed a reduction of ROS formation. The two 
distinct mitochondrial subpopulations differ in their protein and lipid composition, 
protein synthesis, respiration capacity, their sensitivity in response to metabolic 
stress, and Ca2+ retention capacity [77, 124, 181, 206, 210, 229]. SSM appear to be 
the pharmacological target of drugs like diazoxide to induce endogenous 
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cardioprotection [122] and the present data supports the notion in that NO increases 
ROS formation only in SSM. 
The Complex I and III of the respiratory chain are suggested to be the main sources 
of mitochondrial ROS formation [275-277]. Several studies provide strong evidence, 
that mtCx43 regulates ADP stimulated complex 1 respiration via direct interaction. 
Mitochondrial ROS formation was increased following administration of the 
respiratory chain complex 1 inhibitor rotenone in the present study confirming 
previous reports [106, 277]. Interestingly, the NO mediated increase in mitochondrial 
ROS formation in SSM was no longer seen following inhibition of respiratory chain 
complex 1 with rotenone suggesting that S-nitrosated mtCx43 interacts with complex 
1 to increase ROS formation.  
 
4.1.5 Potential side effects of applied NO donors        
The NO donors SNAP and GSNO were used as NO sources in the present study. 
SNAP is one of the most frequently used exogenous S-nitrosothiol (RSNO) while 
GSNO (NO glutathione (GSH) as RSNO) is a endogenous key regulator of the 
cellular redox state and among others modulates metabolic events [45, 222, 243]. 
The regulatory impact of GSNO is biphasic. Besides the modulation via NO, also 
GSH can be covalently attached to cysteine thiols, a process which is called S-
glutathionylation. Therefore GSNO has the potential to cause both S-nitrosation as 
well as S-glutathionylation of proteins and it is postulated that following GSNO 
application a fast transnitrosation reaction is followed by glutathionylation which 
replaces modifications induced by S-nitrosation as well as oxidation [101, 207]. 
Glutathionylation of proteins of the respiratory chain complexes I to III or proteins 
regulating these complexes could be responsible for the lower ROS formation in 
response to antimycin A in GSNO treated samples. Anitmycin A maximizes ROS 
formation by inducing circulation of electrons between respiratory chain complex I 
and III. Since the NO donor SNAP does not influence ROS production during 
inhibition of complex IV it is likely that a glutathionylation reaction induced by GSNO 
inhibits ROS formation in the presence of antimycin A, which might however be time-
dependent. Since the nitrosation reaction precedes the glutathionylation reaction 
following GSNO administration, GSNO might increase ROS formation in the short run 
while ROS formation is decreased at later time points. In theory GSNO might be the 
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optimal cardioprotectant since the short initial increase in ROS formation could trigger 
cardioprotection, while the later on suppression of the production of large amounts of 
ROS preserves from cell death. Further studies need to be performed for clarifying 
the role of GSNO’s glutathionylation reaction in altering mitochondrial function and its 
relevance for cardioprotection. 
 
4.1.6 Increase in SNO of mtCx43 by application of NO donors 
The effects of NO are dose-dependent. Low concentrations of NO nitrosates increase 
mitochondrial respiration, whereas high concentration of S-nitrosate results in a 
reversible inhibition of mitochondrial respiration [36, 38, 42, 47, 270]. Sun et al. 
showed a dose-dependent effect of GSNO in concentrations between 0.1-1 mM 
increasing SERCA2a and α-KGDH activity, whereas F1-ATPase activity was 
inhibited. In the present study ROS formation was estimated with concentrations of 
0.5 mM SNAP, 1 mM, 1 µM, and 48 nM GSNO. The NO donors SNAP and GSNO, 
which were used in the present study, are very poor NO donors delivering NO 
concentrations of about 0.6% and 0.12% of the administered dose [80]. Furthermore 
it is worth mentioning that S-nitrosothiols are very sensitive to daylight [296]. Thus, 
the overall applied NO concentrations should be in the nM range and close to 
physiological concentrations. Indeed, a concentration of 0.1 mM GSNO applied to 
Langendorff perfused hearts induced SNO of mitochondrial proteins to a similar 
extent than an endogenous intervention (IPC) did [263].  
 
4.2 IPC induction of SNO of mtCx43 may mediate 
cardioprotection 
The data of the present study shows that SNO of mtCx43 increases mitochondrial 
dye permeability, K+ fluxes, and ROS formation. Potassium influx through the opening 
of mitoKATP channels and increase in moderate ROS formation are key elements for 
the subsequent inhibition of MPTP opening following ischemia/reperfusion and they 
are two factors necessary for mediating IPC and pharmacological preconditioning 
[29, 115, 167, 245]. Previous studies suggested that NO-induced mtCx43 HC 
opening may be one key mechanism mediating cardioprotection. The following 
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investigations were performed on mitochondria from rat hearts receiving IPC to show 
that SNO of mtCx43 is part of the signal transduction cascade of cardioprotection.  
The open probability of Cx43-formed GJs of myoendothelial cells is increased by 
SNO of cysteine 271 and denitrosation by compartmentalized S-nitrosoglutathione 
reductase decreased GJ permeability [261]. SNO of cysteine 271 of mtCx43 was 
identified by proteomic analysis in rat hearts receiving IPC or control perfusion. 
Unfortunately, the cysteine residue was detected only in low abundance making 
quantification impossible considering that only 5% of the total cellular Cx43 is located 
in mitochondria [230]. Furthermore, only a subpopulation of less than 1% of total 
mtCx43 was found to be SNO modified in resting mitochondria.  
In IPC and control perfused rat hearts cysteine 271 of mtCx43 was found to be SNO 
modified. The cysteine 271 is responsible for increased open probability of GJ 
channels at the plasma membrane [261]. Accordingly, SNO of cysteine 271 is a 
promising candidate for mediating Cx43 HC opening in the inner mitochondrial 
membrane. Proteomic approaches would most likely indicate that a small portion of 
mitochondrial HCs are also opened under resting conditions likely due to SNO protein 
modification.   
Furthermore, SNO of mtCx43 was increased in the LV of mice receiving rIPC. The 
rIPC in a remote organ provides protection from potentially lethal myocardial 
ischemia/reperfusion injury which is proven by several clinical studies [31, 111, 123, 
145]. RIPC also led to increased SNO of mtCx43 in mouse hearts supporting the 
previous observation that IPC induces SNO of mtCx43. Recently, Rassaf et al. 
demonstrated that NO contributes to cardioprotection by rIPC [221]. Accordingly, 
application of nitrite reduced infarct size following ischemia/reperfusion in vivo [116]. 
Nitrite is one of the proposed candidates for transporting the protective signal from 
the remote organ  to the myocardium [221]. The underlying mechanism transmitting 
the protective signal is not fully understood. However, experiments with eNOS 
deficient mice provide evidence that NO generation by eNOS is essential for the 
nitrite mediated cardioprotective effect of rIPC, whereas a cardiac specific role of 
eNOS was excluded [233]. Nitrite is the stable form of NO. The dose dependent 
cytoprotective effect of nitrite functions via its reduction to NO which is dependent on 
myoglobin [79, 116, 273]. Nitrite concentrations of 300–500 nM were detected in the 
circulating blood of mice, which are much higher concentrations compared to nitroso 
species [116, 219]. In the present study, application of 48 nM sodium nitrite induced 
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increased SNO of mtCx43 to an equal extent as rIPC does. This shows that 
concentrations in the nanomolar range are sufficient to induce a similar amount of 
mtCx43 SNO as rIPC did. Therefore, nitrite is a potential pharmacological agent 
which was determined by investigations performed in several models [79, 211]. 
Taken together, the present data indicates that NO and mtCx43 can be linked to the 
signal transduction cascade of cardioprotection. A promising candidate for the 
underlying cardioprotective mechanism could be SNO of mtCx43 cysteine reside 271 
leading to HC opening inducing protection via mitochondrial K+ influx and moderately 
increased ROS formation.     
 
4.3 Study limitations  
The present study demonstrates that NO triggers an increase in mitochondrial 
permeability, particularly for K+, and ROS formation in a Cx43 dependent manner. 
Mitochondrial K+ influx through mitoKATP channels leads to a moderate increase in 
ROS formation inhibiting MPTP opening following ischemia/reperfusion [29, 115, 167, 
245]. This study suggests that two factors necessary for cardioprotection are 
regulated by SNO of mtCx43. This study provides evidence that IPC triggers SNO of 
mtCx43 and increases mitochondrial permeability. In addition, pharmacological 
preconditioning by nitrite increases SNO of mtCx43 to a similar extent as rIPC does, 
giving rise to the notion that NO in physiological concentrations could mediate 
preconditioning via SNO of mtCx43. Taken together, a potential link between NO and 
mtCx43 in the signal transduction cascade of cardioprotection is most likely. 
However, the study lacks direct evidence that SNO of mtCx43 mediates 
cardioprotection by preconditioning because it remains unclear whether or not SNO 
of mtCx43 is sufficient for cardiomyocyte preconditioning. 
Future studies need to be performed to provide evidence that SNO of mtCx43 is 
essential for mediating myocardial PC. This could be done by performing Cx43 
cysteine epitope replacement studies in a stable transfected cell lines or transgenic 
mouse models. Thus, the sites of mtCx43 that are S-nitrosated and are responsible 
for mediating increased mitochondrial ion fluxes and ROS formation could be 
identified. Furthermore, the exact mechanism of mtCx43 HC involvement in 
mediating cardioprotection remains unclear. Further studies are needed to investigate 
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if ion fluxes through mitochondrial Cx43 HC directly mediate preconditioning or if 
increased mtCx43 HC open probability regulates other mitochondrial channels like 
mitoKATP channels.   
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5. Summary  
S-nitrosation of connexin 43 formed channels alters dye uptake in astrocytes and gap 
junctional communication in endothelial cells. Apart from forming channels in the cell 
surface membrane of several cell types, connexin 43 is also located at the inner 
membrane of myocardial subsarcolemmal mitochondria, but not in interfibrillar 
mitochondria. The absence or pharmacological blockade of mitochondrial connexin 
43 decreases mitochondrial dye and potassium uptake. A lack of mitochondrial 
connexin 43 is associated with the loss of cardioprotection by ischemic 
preconditioning, which is mediated by formation of reactive oxygen species.  
Whether or not mitochondrial Lucifer Yellow, ion uptake, or reactive oxygen 
generation are affected by S-nitrosation of mitochondrial connexin 43 and whether or 
not cardioprotective interventions influence S-nitrosation of mitochondrial connexin 43 
remains unknown. 
Subsarcolemmal mitochondria from rat hearts showed an increased Lucifer Yellow 
uptake in response to nitric oxide donors (S-nitroso-N-acetyl-DL-penicillamine 
(SNAP): 38.4 ± 7.1%, p<0.05; S-nitrosoglutathione (GSNO): 28.1 ± 7.4%, p<0.05) 
and an increased refilling rate of potassium (SNAP: 227.9 ± 30.1%, p<0.05; GSNO: 
122.6 ± 28.1%, p<0.05). These effects were abolished following blockade of connexin 
43 hemichannel by carbenoxolone as well as in interfibrillar mitochondria, which lack 
connexin 43. Unlike potassium, the sodium permeability was not affected by 
application of nitric oxide. Furthermore, mitochondrial reactive oxygen species 
formation was enhanced in response to nitric oxide application compared to control 
treatment group (SNAP: 22.9 ± 1.8%, p<0.05; GSNO: 40.6 ± 7.1%, p<0.05), but 
decreased following nitric oxide treatment in interfibrillar mitochondria compared to 
control treated interfibrillar mitochondria (SNAP: 14.4 ± 4%, p<0.05; GSNO: 13.8 ± 
4%, p<0.05). Administration of nitric oxide donors to isolated subsarcolemmal 
mitochondria or nitrite application into the cavity of left ventricles in mice in vivo 
enhanced S-nitrosation of mitochondrial connexin 43 by 109.2 ± 15.8% and by 59.3 ± 
18.2%, respectively (p<0.05). Ischemic preconditioning by 4 cycles of ischemia and 
reperfusion, enhanced S-nitrosation of mitochondrial connexin 43 by 41.6 ± 1.7% 
(p<0.05) in comparison to subsarcolemmal mitochondria from control perfused rat 
hearts.  
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These data suggest that S-nitrosation of mitochondrial connexin 43 increases 
mitochondrial permeability, especially for potassium and leads to increased formation 
of reactive oxygen species. The increased amount of S-nitrosated mitochondrial 
connexin 43 by ischemic preconditioning or nitrite administration may link nitric oxide 
and connexin 43 in the signal transduction cascade of cardioprotection by 
preconditioning.  
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6. Zusammenfassung  
Neben der Bildung von transmembranen Kanälen an der Zelloberfläche, ist Connexin 
43 auch in der inneren Membran von subsarkolemmalen Mitochondrien lokalisiert. In 
interfibrillären Mitochondrien ist Connexin 43 jedoch nicht nachweisbar. Die 
Abwesenheit oder pharmakologische Inhibierung von mitochondrialem Connexin 43 
verringert die mitochondriale Farbstoff- und Kaliumaufnahme und führt zum Verlust 
von Kardioprotektion durch ischämische Präkonditionierung, welche durch die 
moderate Produktion von reaktiven Sauerstoffspezies ausgelöst wird. Die S-
Nitrosierung von Connexin 43 gebildeten Membrankanälen führt zu einer veränderten 
Farbstoffaufnahme in Astrozyten und beeinflusst die auf Gap Junctions basierende 
Kommunikation zwischen den Zellen des Endothels.    
Gegenstand der vorliegenden Untersuchung ist die Analyse der S-Nitrosierung von 
mitochondrialem Connexin 43 und dessen Einfluss auf die mitochondriale 
Farbstoffaufnahme, mitochondriale Ioneneinströme, und Formierung reaktiver 
Sauerstoffspezies. Zusätzlich wurde die S-Nitrosierung vom mitochondrialem 
Connexin 43 nach kardioprotektiven Interventionen quantifiziert.      
In subsarkolemmalen Mitochondrien von Rattenherzen, die mit den 
Stickstoffmonoxid-Donatoren S-nitrosoglutathione (GSNO) und S-nitroso-N-acetyl-
DL-penicillamine (SNAP) behandelt wurden, war die Lucifer Yellow 
Farbstoffaufnahme (SNAP: 38.4 ± 7.1%, p<0.05; GSNO: 28.1 ± 7.4%, p<0.05) und 
die Geschwindigkeit des Kaliumstroms erhöht (SNAP: 227.9 ± 30.1%, p<0.05; 
GSNO: 122.6 ± 28.1%, p<0.05). Die Wirkung der Stickstoffmonoxid-Donatoren wurde 
durch Inhibierung der Connexin 43 Hemikanäle aufgehoben und war in interfibrilären 
Mitochondrien, die kein Connexin 43 enthalten, nicht nachweisbar. Im Gegensatz zu 
Kalium, war die Natrium-Permeabilität durch die Verabreichung von 
Stickstoffmonoxid nicht beeinflussbar. Außerdem wurde die mitochondriale 
Produktion von reaktiven Sauerstoffspezies durch die Zugabe von Sticksfoffmonoxid-
Donatoren (SNAP und GSNO) in subsarkolemmalen Mitochondrien gesteigert 
(SNAP: 22.9 ± 1.8%, p<0.05; GSNO: 40.6 ± 7.1%, p<0.05). Im Gegensatz dazu 
führte die Zugabe von Stickstoffmonoxid in interfibrillären Mitochondrien zu einer 
Reduktion der Produktion von reaktiven Sauerstoffspezies (SNAP: 14.4 ± 4%, 
p<0.05; GSNO: 13.8 ± 4%, p<0.05). Die Verabreichung von Stickstoffmonoxid-
Donatoren oder die Injektion von Nitrit in den linken Ventrikel von Mäusen in vivo 
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führte zu einer Erhöhung der S-Nitrosierung von Connexin 43 in subsarkolemmalen 
Mitochondrien um 109.2 ± 15.8% bzw. 59.3 ± 18.2%, (p<0.05). Ischämische 
Präkonditionierung, hervorgerufen durch vier Zyklen von Ischämie und Reperfusion, 
erhöhte die S-Nitrosierung vom mitochondrialem Connexin 43 um 41.6 ± 1.7% 
(p<0.05) im Vergleich zu subsarkolemmalen Mitochondrien von kontroll-perfundierten 
Rattenherzen. 
Die im Rahmen dieser Arbeit erfassten Daten zeigen, dass S-Nitrosierung von 
mitochondrialem Connexin 43 die mitochondriale Permeabilität für Farbstoff und 
besonders für Kalium-Ionen erhöht. Die S-Nitrosierung von mitochondrialem 
Connexin 43 führt zu einer erhöhten Produktion von reaktiven Sauerstoffspezies. 
Ischämische Präkonditionierung als auch die der Verabreichung von Nitrit führte zu 
einer erhöhten Menge an S-nitrosiertem mitochondrialen Connexin 43. 
Schlussfolgernd liegt es nahe, dass die S-Nitrosierung von mitochondrialem 
Connexin 43 für die Vermittlung des kardioprotektiven Signals von Bedeutung ist. 
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List of Abbreviations 
18αGA  18α-glycyrrhetinic acid 
aa   amino acid  
ACN   acetonitrile  
ADP   adenosine diphosphate 
Akt   protein kinase B 
AM   acetoxy methyl  
AMP   adenosine monophosphate 
ANOVA  analysis of variance  
ATP   adenosine triphosphate 
Bcl-2   B-cell lymphoma 2 
BIAM   biotinylated iodoacetamide 
BS3   bis(sulfosuccinimidyl)suberate   
BSA   bovine serum albumin 
Ca2+   calcium 
CBX   carbenoxolone 
cGMP   cyclic guanosine monophosphate 
CID   collision-induced dissociation 
CL   cytoplasmic loop 
Cl-   chloride 
CsA    cyclosporine A  
C-terminal  carboxyl-terminal  
Cx   connexin  
dH2O   distilled water 
Da   Dalton 
DMSO   dimethyl sulfoxide 
DTT   dithiothreitol  
E   extracellular loop 
EDTA   ethylenediaminetetraacetic acid 
EGTA   ethylene glycol tetraacetic acid 
ERK   extracellular signal-regulated protein kinase 
et al.   and others (et alii) 
EtOH   ethanol  
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FCCP   p-triflouromethoxyphenylhydrazone 
g   gravitational force  
GAP26  connexin mimetic peptide 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
GJ   gap junction 
G-protein  guanosine nucleotide-binding protein 
GSK   glycogen synthase kinase 
GSNO   S-nitrosoglutathione  
H+   proton 
HC   hemichannel 
HDAC   histone deacetylase 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid   
HRP   horseradish peroxidase 
IgG    immunoglobulin G 
IFM   interfibrillar mitochondria 
i.p.   intra peritoneal 
IP   immunoprecipitation   
IPC    ischemic preconditioning  
JAK   Janus kinase 
JNK    c-Jun N-terminal kinase 
kDa   kilo Dalton  
kg   kilogram   
λex    fluorescence excitation wavelength  
λem   fluorescence emission wavelength  
LC-MS  liquid chromatography-mass spectrometry    
Li   Lithium  
LY    Lucifer Yellow CH dilithium salt  
MAPK   mitogen-activated protein kinase 
mitoKATP   ATP-dependent potassium 
mmHg  millimeters of mercury 
MnSOD  manganese superoxide dismutase 
MOPS  4-morpholinepropanesulfonic acid 
MPTP   mitochondrial permeability transition pore 
MS   mass spectrometry  
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mtCx43   mitochondrial connexin 43 
n   sample size 
Na+   sodium 
NaCl   sodium chloride 
NAD+   nicotinamide adenine dinucleotide 
NADPH  nicotinamide adenine dinucleotide phosphate 
NEM   N-ethylmaleimide  
NO       nitric oxide  
NOS   nitric oxide synthase 
ns   not significant  
N-terminal  amino-terminal  
p   significance level  
PBFI    potassium-binding benzofuran isophthalate 
PBS    phosphate buffered saline 
PC    preconditioning  
pH    pondus Hydrogenii or potentia Hydrogenii 
PK   protein kinase 
PKA   protein kinase A  
PKC   protein kinase C 
PKG   protein kinase G 
rIPC   remote ischemic preconditioning  
RISK   reperfusion injury salvage kinases  
RITC-dextran rhodamine B isothiocyanate-dextran 10S  
ROS    reactive oxygen species  
rpm   rounds per minute 
RV   right ventricle  
SAFE   survivor activating factor enhancement 
SBFI   sodium-binding benzofuran isophthalate 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   standard error of the mean 
Ser368  serine residue 368  
SERCA  sarcoendoplasmic reticulum calcium transport ATPase 
SNAP   S-nitroso-N-acetyl-DL-penicillamine 
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SNO   S-nitrosation    
SSM   subsarcolemmal mitochondria 
STAT   signal transducer and activator of transcription  
TEA   triethanolamine 
TM   transmembrane  
TMA   trimethylaluminium 
TNF-α   tumor necrosis factor 
TOM20  translocase of the outer membrane receptor unit 20 
Tris   tris(hydroxymethyl)aminomethane)  
U   units 
UV   ultraviolet 
VDAC   voltage dependent anion channel 
v-src   viral sarcoma  
v/v    volume per volume  
wt/vol   weight per volume   
yj   ion energy  
 
S.I. units, elements, and chemicals were abbreviated according to international 
standards and are not listed here. 
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